The fungal intestinal microbiota predict the development of bronchopulmonary dysplasia in very low birthweight newborns

Kent A. Willis[1,2], Mary Silverberg[1], Isaac Martin[1], Ahmed Abdelgawad[1], Kosuke Tanaka[1], Ibrahim Karabayir[3], Brian A. Halloran[1], Erin D. Myers[4], Jay P. Desai[5], Catrina T. White[5], Charitharth V. Lal[1], Namasivayam Ambalavanan[1], Brian M. Peters[6], Viral G. Jain[1], Oguz Akbilgic[3,7], Laura Tipton[8], Tamás Jilling[1], Stephania A. Cormier[9,10], Joseph F. Pierre[11], and Ajay J. Talati[5,12]

[1]Division of Neonatology, Department of Pediatrics, Heersink School of Medicine, The University of Birmingham, Birmingham, AL, USA. [2]Microbiome Center, The University of Alabama at Birmingham, Birmingham, AL, USA. [3]Division of Cardiology, Department of Medicine, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, NC, USA. [4]College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, USA. [5]Division of Neonatology, Department of Pediatrics, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, USA. [6]Department of Clinical Pharmacy and Translational Science, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, USA. [7]Epidemiological Cardiology Research Center, Wake Forest University, Winston-Salem, NC, USA. [8]Department of Data Science, Analytics, and Visualization, Chaminade University of Honolulu, Honolulu, HI, USA. [9]Department of Biological Sciences, Louisiana State University, Baton Rouge, LA, USA. [10]Pennington Biomedical Research Center, Baton Rouge, LA, USA. [11]Department of Nutritional Sciences, College of Agricultural and Life Sciences, The University of Wisconsin – Madison, Madison, WI, USA. [12]Department of Obstetrics and Gynecology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, USA.

Abstract

Rationale: Bronchopulmonary dysplasia (BPD) is the most common morbidity affecting very preterm infants. Gut fungal and bacterial microbial communities contribute to multiple lung diseases and may influence BPD pathogenesis.

Methods: We performed a prospective, observational cohort study comparing the multikingdom fecal microbiota of 144 preterm infants with or without moderate to severe BPD by sequencing the bacterial 16S and fungal ITS2 ribosomal RNA gene. To address the potential causative relationship between gut dysbiosis and BPD, we used fecal microbiota transplant in an antibiotic-pseudohumanized mouse model. Comparisons were made using RNA sequencing, confocal microscopy, lung morphometry, and oscillometry.

Results: We analyzed 102 fecal microbiome samples collected during the second week of life. Infants who later developed BPD showed an obvious fungal dysbiosis as compared to infants without BPD (NoBPD, p = 0.0398, permutational multivariate ANOVA). Instead of fungal communities dominated by *Candida* and *Saccharomyces*, the microbiota of infants who developed BPD were characterized by a greater diversity of rarer fungi in less interconnected community architectures. On successful colonization, the gut microbiota from infants with BPD augmented lung injury in the offspring of recipient animals. We identified alterations in the murine intestinal microbiome and transcriptome associated with augmented lung injury.

Conclusions: The gut fungal microbiome of infants who will develop BPD is dysbiotic and may contribute to disease pathogenesis.Conclusions: The gut fungal microbiome of infants who will develop BPD is dysbiotic and may contribute to disease pathogenesis.

Trial Registration: NCT03229967.

Keywords: Multikingdom microbiome, gut microbiome; fungal microbiome; mycobiome; preterm infant; chronic lung injury

Introduction

Bronchopulmonary dysplasia (BPD) is the most common morbidity of prematurity [1, 2]. Disproportionately affecting the most premature newborns, BPD exacts a devastating toll on the immature lung, impairing alveolarization and disrupting vascularization [3]. Despite the considerable, life-long morbidity and staggeringly high mortality of BPD [1, 2], meaningful interventions to modulate lung injury in preterm newborns remain beyond reach [4]. While environmental triggers, such as exposure to hyperoxia, have been described, modulators of the disease remain elusive.

The gut-lung axis is a recently described phenomenon whereby intestinal commensal microbes may project their influence on lung physiology and pathology [5, 6]. Examples of this connection are described in models of neonatal pneumonia [7, 8] and asthma [9, 10]. Intestinal microbes can influence the lung directly via the production of metabolites and indirectly by informing immune mechanisms that module lung injury and recovery [7, 9]. While previous work has focused on bacteria, other commensal organisms, such as fungi, may prove to be critical stimulators of immunity [9, 11]. In early life, gut fungal communities (the mycobiome) appear causally linked to pulmonary immune development [9]. This may make the mycobiome an important modulator of lung injury in BPD. However, the composition of fungal communities in BPD has not been explored.

We performed a prospective, observational cohort study of very low birthweight (VLBW) preterm newborns to determine if the gut mycobiota composition predicts BPD development. The principal outcome was moderate to severe BPD or death before BPD adjudication. To interrogate causality, we also performed fecal microbiota transplant (FMT) into antibiotic-pseudohumanized mice. Due to their importance to immune development, we hypothesized that the composition of the mycobiome would predict BPD in VLBW infants and that this effect would be transferable to *in vivo* models of BPD. Here, we show the gut-lung axis may influence the development of BPD and that dysbiotic gut mycobiota can augment BPD-like illness via FMT.

Methods

Detailed methods are provided in the online supplement.

Study Subjects:

This study was a prospective observational cohort study of inborn, VLBW (< 1500g) preterm newborns without known congenital anomalies or immunodeficiencies conducted at a Level IIIB academic neonatal ICU (MiBPD study: NCT03229967). We defined BPD by the NICHD Workshop definition [12]. For dichotomous analyses, 'BPD' represents the composite outcome of Grade II to III BPD or death before 36 weeks of gestation, with the infants without BPD defined as 'NoBPD' [13]. Because critically ill premature infants often do not produce stool or only pass meconium during the first week of life, this study utilized the first non-transitional stool produced during the second week of life. Infants that either did not stool or only passed a meconium stool during the second week of life were excluded from this analysis. At the time of this study, probiotics were not administered in this unit. A second cohort from a different Level IV NICU provided the samples for FMT to create antibiotic-pseudohumanized mice.

Animal experimental protocol:

To create pseudo-humanized mice with a BPD or NoBPD-associated microbiome engrafted throughout the critical period for BPD development [14–16], we purchased conventional specific pathogen-free (SPF) C57Bl6/J mice from the Jackson Laboratory. We randomized them into cages of four female mice each. After acclimatization, we exposed the mice to a week of systemically absorbable antibiotics (penicillin VK, cefoperazone sodium, and clindamycin sodium 1g/L), followed by gastric gavage of 200 uL of polyethylene glycol 3350 at 425 g/L, then another week of non-absorbable antibiotics (ertapenem sodium, vancomycin sodium, and neomycin sodium 1g/L). With the native microbiota thus disrupted, we engrafted human microbiota from infants with BPD or NoBPD by FMT. We bred

these mice to generate neonatal offspring we termed BPD-FMT or NoBPD-FMT. Pooled litters of neonates with the same exposure were then randomized to either normoxia (FiO$_2$ 0.21) or hyperoxia (FiO$_2$ 0.85) exposure from postnatal day (P) 3-14 using a standardized model of BPD [17, 18].

Bacterial and fungal metagenomic sequencing:
For the human cohorts, the first non-transitional stool produced during the second week of life was collected in oxygen-reduced PBS with a sterile spatula immediately following evacuation into a clean diaper. For mouse samples, we collected the whole left lung and terminal ileum [19]. Microbial DNA was extracted, amplified, and sequenced as described [20, 21]. Negative and positive controls were collected and passed through the DNA extraction and sequencing steps. Sequence data were processed with *QIIME 2* [22] and *DADA2* [23], decontaminated using *PERFect* [24], and analyzed in R. Details regarding data processing and ecological analyses are available in the online supplement.

Statistical analysis:
Statistical analyses were performed in SPSS (IBM), Prism 9 (GraphPad), Python, or R. Animal experiments are representative of 2-3 pooled mouse litters per human donor with at least 3 human donors per experimental group and analyzed by two-way ANOVA with a Šidák correction.

Results

We performed a prospective, observational cohort study of 144 VLBW infants in neonatal intensive care. 102 infants produced their first non-meconium stool during the second week of life, from which we characterized the intestinal microbiota. Cohort characteristics are described in table 1. One infant was excluded due to inadequate sequencing quality, and one for incomplete clinical data. The remaining 42 infants either did not stool or only passed a meconium stool during this period and were excluded. Characteristics of excluded infants, which did not differ from the study cohort, are in table S2.

Dysbiosis of the gut microbiota in infants with BPD.
We first compared the intestinal microbiota of preterm infants who later developed BPD to infants who did not develop BPD (NoBPD cohort). As shown in figure 1, the fungal intestinal microbiota (mycobiome) of BPD infants differed in community diversity, composition, and interconnectivity from NoBPD infants. We did not identify differences in the bacterial microbiome.

For alpha diversity, the within-group variation exceeded the between-group differences for both the mycobiome and the microbiome. The alpha diversity of the mycobiome was greater in BPD as quantified by the Shannon and Simpson diversity indices (p = 0.0010 and 0.0021, Mann-Whitney, figure 1a). The alpha diversity of the bacterial microbiome was similar (figure 1b).

We used several complementary methods to quantify beta diversity. As visualized by principal coordinates analysis, disease status produced divergent clustering of the mycobiome (figure 1c). The mycobiome is differently composed in BPD infants (p = 0.0209, permutational multivariate ANOVA (PERMANOVA)). We verified this was not a false positive due to unequal dispersion with permutational multivariate analysis of dispersion (PERMDISP, p = 0.4393). We performed biplot analysis of principal components analysis graphs to identify which amplicon sequence variants (ASVs) produced these compositional differences. We determined that multiple ASVs belonging to the genera *Candida* and an ASV aligning to *Aureobasidium* made the most significant contributions to the structure of the mycobiome. However, the microbiome was not statistically different (p = 0.06109, PERMANOVA, p = 0.365, PERMDISP, figure 1d). Biplot analysis showed *Enterococcus* and multiple *Klebsiella* ASVs contributed to the overall bacterial community structure.

To quantify the interconnectivity of these microbial communities, we used a novel cross-domain extension of SPIEC-EASI [11] to build multikingdom interaction networks (figure 1g-h). Compared to NoBPD infants, BPD infants have fewer fungal than bacterial edges but a similar number of nodes (figure S2e). Together, this creates multikingdom interaction networks that are sparser for BPD infants, with fewer fungi-to-fungi and fungi-to-bacterial interactions than NoBPD infants.

Figure 1. The fungal gut microbiota is altered in infants that will develop bronchopulmonary dysplasia. (*a*) Fungal alpha diversity as quantified by the Shanon and Simpson indices of infants with moderate to severe bronchopulmonary dysplasia or death prior to 36 weeks gestation (BPD) to those without (NoBPD). (*b*) Bacterial alpha diversity. (*c*) Principal coordinates analysis (PCoA) of Bray-Curtis dissimilarity displaying differences in fungal beta diversity (p = 0.0398, permutational multivariate analysis of ANOVA, PERMANOVA. p = 0.4393, permutational multivariate analysis of dispersion, PERMDISP). Ellipses indicate the 95% confidence interval. (*d*) Biplot of principal components analysis (PCA) with fungal community composition driven by amplicon sequence variants (ASVs) aligning to the genera *Candida* and *Aureobasidium* (p = 0.0466). (*e*) PCoA of Bray-Curtis dissimilarity displaying bacterial beta diversity (p = 0.06109, PERMANOVA. p = 0.365, PERMDISP). (*f*) Biplot of PCA of bacterial community composition (p = 0.0462). (*g* and *h*) SPIEC-EASI network analysis shows that BPD infants formed sparser multikingdom networks than NoBPD infants. See also supplemental figures 2 and 3.

We used DESeq2 to identify differentially abundant genera. For the mycobiome, the genus *Candida* was more abundant in NoBPD infants, while *Mortierella* was increased in BPD infants (figure S2). For the bacteriome, we detected increases in the Family Staphylococcaceae and the genus *Veillonella*. Together, these analyses indicate the gut mycobiome of infants that will develop BPD is unique. It was characterized by a lower abundance of *Candida* and a higher number of rarer fungal taxa, including *Mortierella*, arranged in more sparse and less interconnected multikingdom networks.

Fungal dysbiosis predicts BPD development.
To test the predictive potential of the mycobiota, we first developed random forest machine-learning models using the mycobiome or microbiome as an exploratory analysis (figure S4). Next, we developed a LightGBM model using clinical variables known to predict the development of BPD from the Neonatal BPD Outcomes Predictor [25, 26] and higher-order taxa microbiota data (figure 2). After five-fold cross-validation and Bayesian hyperparameter tuning, the model predicted the risk of developing BPD in the unseen validation set with an area under the curve of 0.81 (CI$^{95\%}$ 0.61-1.00), with a sensitivity of 80% and specificity of 89%, positive predictive value of 89%, and an F1-score of 0.89 (figure 2). For the composite outcome of severe BPD or death, a second model obtained an area under the curve of 0.89 (CI$^{95\%}$ 0.76-1.00), with a sensitivity of 75% and specificity of 86%, a positive predictive value of 90%, and F1-score of 0.82. Intriguingly, in variable importance analysis, several fungal phyla's relative abundance strongly contributed

to the model (figure S4e), including the minor phyla Mortierellomycota and Rozellomycota and the major phyla Ascomycota and Basidiomycota. The fungal taxa outperformed several well-described clinical characteristics and all bacterial phyla except Bacteroidata.

Sex-specific differences in the composition of the mycobiome.
Due to known sex-specific differences in BPD [27, 28], we predetermined to test if sex-specific features exist in the neonatal mycobiome (figures 3 and S4-5). Shannon and Simpson diversity of the mycobiome and bacteriome did not differ between those assigned female (AFAB) or male at birth (AMAB) figure 3a-b). Fungal community composition differed for all groups (*p* = 0.0407, PERMANOVA; *p* = 0.5957, PERMDISP, figure 3c). AFAB infants with BPD and NoBPD clustered closer than infants AMAB (figure 3c). DESeq2 identified differences in the abundance of the fungal genera *Mortierella* and *Pseudeurotium* in AMAB infants who later developed BPD (figure S6a-b). SPIEC-EASI network analysis identified greater interconnectivity of infants with NoBPD regardless of sex assigned at birth (figure 3e-h, S6e-f). Infants AMAB had fewer fungal edges than infants AFAB, but the number of edges was reduced only in infants AMAB that would develop BPD (figure S6c). These differences produced sparser networks in infants AMAB, with the least interconnected networks in infants AMAB with BPD. From these analyses, we conclude that sex-specific differences in the composition of the mycobiome are the strongest in infants AMAB that will develop BPD.

Figure 2. The mycobiota predicts the development of BPD. (*a*) A light gradient-boosted machine learning model (LightGBM) with Bayesian hyperparameter tuning developed from clinical data and phylum-level microbiome data indicates that key members of the mycobiome predict the development of BPD. CRIB-II, critical risk index for babies-II. CRP, c-reactive protein. FiO_2 (dol 7), average fraction of inspired oxygen on the 7th day of life. FiO_2 (dol 3), average fraction of inspired oxygen on the 3rd day of life. I/T, immature to total lymphocyte ratio on admission complete blood count. BMI, body mass index. Neutrophils, neutrophil count on admission complete blood count. See also supplemental figure 4.

Fecal microbiota transfer transmits a severe phenotype of BPD.

To test if alterations in the gut mycobiome that we found preceded the development of BPD could augment lung injury, we transferred the gut microbiome from infants with either BPD or NoBPD into mice. Because the effects of bacterial and fungal members of the microbiome are interdependent, we transferred intact microbial communities. Following antibiotic preparation, recipient maternal mice were randomly orally inoculated with anoxic fecal samples from donor infants. These mice were bred, and the resulting newborn mice were exposed to hyperoxia to induce BPD-like lung injury (figure 4a).

Neonatal mice that received BPD-associated microbiomes (BPD-FMT) had more significant histological lung injury when exposed to hyperoxia than mice that received NoBPD-associated microbiomes (NoBPD-FMT) (Greater mean linear intercept and reduced radial alveolar count, $p < 0.0001$ and $p = 0.0005$, two-way ANOVA, figure 4b-c). Functionally, BPD-FMT mice had increased pulmonary resistance ($p = 0.0015$) and decreased compliance ($p = 0.0196$). We used immunohistochemistry and morphometry to measure neointimal changes consistent with pulmonary hypertension (figure 4d) and identified BPD-FMT mice had reduced vascular density of 20-50 µm diameter vessels ($p = 0.0065$, figure 4e).

We next used RNA-seq to quantify transcriptomic changes in the lungs of these mice. Principal components analysis confirmed unique global transcriptomic changes in the lungs of mice by both FMT and hyperoxia exposure (figure 4f). Volcano plots show a clear difference in the response of NoBPD-FMT (figure 4g) and BPD-FMT (figure 4h) to hyperoxia exposure. We identified unique alterations in lung injury (table S5), lectins and other fungal interacting

Figure 3. Sex-specific differences in infants that will develop BPD. (*a*) Fungal alpha diversity in infants in infants assigned male (AMAB) or female at birth (AFAB) with NoBPD or BPD. (*b*) Bacterial alpha diversity. (*c*) Principal coordinates analysis (PCoA) of Bray-Curtis dissimilarity showing differences in the mycobiome for each sex and disease state (p = 0.0407, PERMANOVA, p = 0.5957, PERMDISP). Ellipses indicate the 95% confidence interval. (*d*) PCoA of Bray-Curtis dissimilarity of the bacterial microbiome (p = 0.3196, PERMANOVA. p = 0.6439). (*e-h*) SPIEC-EASI network analysis shows that BPD infants AMAB formed the sparsest networks. See also supplemental figures 5 and 6.

genes (table S6), and antimicrobial peptides (figure S12, table S7). To identify genes uniquely regulated in mice exposed to FMT, we compared their lung transcriptome to hyperoxia or normoxia-exposed conventional mice (figure 5i). 210 genes were uniquely regulated in BPD-FMT mice (table S8) and 363 genes in NoBPD-FMT mice (table S9) as compared to 793 uniquely regulated genes in the conventional mice. Acute phase response and pathogen-activated cytokine storm signaling was increased BPD-FMT but not in NoBPD-FMT mice by pathway analysis (figure S13). Conventional mice had increased angiogenic, interleukin-6, and -17 signaling that was not observed in either FMT group.

Fecal microbiota transfer alters the neonatal mouse microbiome.

We also characterized the mouse lung and gut microbiomes to identify how FMT and hyperoxia exposure influence their ecology. In the mouse gut and lung, 79% and 69% of the genera were shared with human donor microbiomes. Beta but not alpha diversity was significantly different for the gut mycobiome (*p* = 0.0062, PERMANOVA figure 5a) and microbiome (*p* = 0.0167, figure 5b). In the lungs, only the microbiome was uniquely composed (*p* = 0.0103, PERMANOVA, figure 5c-d). From these analyses, we conclude that a BPD-associated mycobiome is transferable to neonatal mice and results in augmented lung injury from hyperoxia exposure.

Discussion

BPD is the most common morbidity and severe chronic respiratory disease in newborns [4]. Considerable heterogeneity exists in its clinical phenotype, and effective means to predict and modulate disease

remain unavailable because the underlying etiology remains unclear. Here, we sought new answers in the gut. We found that in preterm neonates who would eventually develop BPD, the fungal intestinal microbiota differed several weeks before diagnosis from neonates who did not develop BPD (NoBPD cohort). Furthermore, these differences were driven by fungal commensals. With FMT, we showed that gut microbiota transferred from the BPD cohort could augment lung injury as compared to microbiota transferred from the NoBPD cohort. Our findings suggest the gut-lung axis may play a crucial role in the etiology of BPD.

Fungi are vital members of the human microbiota [29]. However, unlike bacterial commensals, their non-pathological and non-parasitic functions remain poorly understood [29]. So, while the microbiome has recently emerged as a contributor to clinical heterogeneity in adult patients in intensive care [30–38], our knowledge of fungal commensals in newborn respiratory disease is limited [39]. Here, in one of the most extensive studies of the multikingdom intestinal microbiome in preterm newborns, we show that the composition of gut mycobiome during the second week of life predicts the development of BPD. The abundance of certain higher-order fungal taxa was similarly predictive of the risk of developing BPD as well-established clinical criteria [25, 26, 40]. Intriguingly, we also identified robust sex-specific differences between infants who would develop BPD that were not observed in infants who did not develop BPD. In light of recent sex-specific differences in the development of BPD detected by single-cell transcriptomics [27, 41–43], this is an interesting finding worth further investigation.

Collectively, our analyses found that the composition of the intestinal mycobiota of infants that would develop NoBPD was more uniform, whereas those that eventually developed BPD had more disparate mycobiota. This suggests that a particular pattern of mycobiota development may be necessary to impart resistance to the development of BPD, and failure to do so in various ways is associated with disease development. A more robust health-associated microbiome with a less specific disease-associated microbiome is a well-described ecological pattern termed the Anna Karenina phenomenon [44]. This paradigm holds for other aspects of the pathogenesis of BPD [45]; therefore, this finding fits within our broader understanding of the disease.

A previous study of the bacterial microbiota identified a divergence over time between the bacterial community composition in the gut and lungs of preterm infants that would eventually develop BPD [46], suggesting that a gut-lung axis may influence the development of BPD. While the mechanisms underlying the gut-lung axis require further exploration in BPD, work in other childhood diseases has suggested some potential mechanisms. Mouse models of childhood asthma suggest intestinal fungi are more immunostimulatory than bacteria, while intestinal bacteria are more responsible for producing metabolites detectable in the host's serum [9]. Gut intestinal fungi, mainly the yeast *Candida albicans*, are known to provoke strong immune responses in the host [47]. Indeed, monocolonization with *Candida* can stimulate postnatal immune development [48]. The greater abundance of *Candida*-dominated communities we observed in NoBPD infants is intriguing in this regard.

Limitations of this study include that we transplanted whole fecal samples in the mouse FMT experiment. While we analyzed the microbiota transferred to the neonatal mice, it remains unclear which components of this complex mix of microbes, metabolites, and nutrients modulate lung injury. Future experiments may benefit from a multiomic approach to identify and validate potential candidate microbes or metabolites. Similarly, it is currently not feasible to confine the transfer of microbes to only one organ system. Quantifying how spillover from FMT might affect other host organs, such as the lungs, remains challenging. A strength of this study was the rigorous exploration of the multikingdom microbiota using the most up-to-date bioinformatic techniques [39] and the demonstration that the mycobiome effect was transferable by FMT.

Conclusions:
In this prospective, observational cohort study of VLBW preterm newborns, baseline compositional differences in the gut mycobiome predicted the eventual development of BPD. Furthermore, we showed that this dysbiotic mycobiota could augment lung injury in a mouse model of BPD. These findings suggest that the gut mycobiota can modulate lung injury and represent a therapeutic target in newborn lung disease.

Figure 4. Fecal microbiota transfer from infants with BPD augments lung injury in mice. (*a*) Experimental schematic. (*b-d*) Histomorphological analysis and forced oscillometry of the lungs of 14-day-old neonatal mice born to pseudo-humanized mice with fecal microbiota transport from BPD-associated microbiomes (BPD-FMT) or NoBPD-associated microbiomes (NoBPD-FMT). Scale bars, 100 μm. (*d-e*) Immunohistochemistry of alpha-smooth muscle actin and von Wilibrand's Factor showing vascular changes consistent with early pulmonary hypertension (*d*) and reduced vascular density of 20-50 μm vessels (*e*). Scale bars, 20 and 50 μm. (*f-i*) Hyperoxia exposure induces different transcriptomic profiles in the lungs in BPD-FMT or NoBPD-FMT mice by RNA-seq. (*f*) Principal components analysis of global transcriptome by both disease and FMT. (*g*) Volcano plot of the hyperoxia-induced transcriptomic alterations in NoBPD-FMT. (*h*) Volcano plot of hyperoxia-induced transcriptomic alterations in BPD-FMT. (*i*) Venn diagram showing unique gene regulation in both BPD-FMT and NoBPD-FMT mice as compared to conventional specific pathogen-free mice (SPF). FiO₂, fraction of inspired oxygen. Schematic created using BioRender.com. See supplemental figures 12-13

specific differences in the development of BPD detected by single-cell transcriptomics (34, 49–51), this is an interesting finding worth further investigation.

Collectively, our analyses found that the composition of the intestinal mycobiota of infants that would develop PPRD was more uniform, whereas those that eventually developed BPD had more disparate mycobiota. This suggests that a particular pattern of mycobiota development may be necessary to impart resistance to the development of BPD, and failure to do so in various ways is associated with disease development. A more robust health-associated microbiome with a less specific disease-associated microbiome is a well-described ecological pattern

termed the Anna Karenina phenomenon (52). This paradigm holds for other aspects of the pathogenesis of BPD (53); therefore, this finding fits within our broader understanding of the disease.

A previous study of the bacterial microbiota identified a divergence over time between the bacterial community composition in the gut and lungs of preterm infants that would eventually develop BPD (54), suggesting that a gut-lung axis may influence the development of BPD. While the mechanisms underlying the gut-lung axis require further exploration in BPD, work in other childhood diseases has suggested some potential mechanisms. Mouse models of childhood asthma suggest intestinal fungi are more

immunostimulatory than bacteria, while intestinal bacteria are more responsible for producing metabolites detectable in the host's serum (11). Gut intestinal fungi, mainly the yeast *Candida albicans*, are known to provoke strong immune responses in the host (55). Indeed, monocolonization with *Candida* can stimulate postnatal immune development (56). The greater abundance of *Candida*-dominated communities we observed in PPRD infants is intriguing in this regard.

Limitations of this study include that we transplanted whole fecal samples in the mouse FMT experiment. While we analyzed the microbiota transferred to the neonatal mice, it remains unclear which components of this complex mix of microbes, metabolites, and nutrients modulate lung injury. Future experiments may benefit from a multiomic approach to identify and validate potential candidate microbes or metabolites. Similarly, it is currently not feasible to confine the

transfer of microbes to only one organ system. Quantifying how spillover from FMT might affect other host organs, such as the lungs, remains challenging. A strength of this study was the rigorous exploration of the multikingdom microbiota using the most up-to-date bioinformatic techniques (47) and the demonstration that the microbiome effect was transferable by FMT.

Conclusions:

In this prospective, observational cohort study of VLBW preterm newborns, baseline compositional differences in the fungal intestinal microbiome predicted the eventual development of BPD. Furthermore, we showed that this dysbiotic microbiota could augment lung injury in a mouse model of BPD. These findings suggest that the gut microbiota can modulate lung injury and represents a therapeutic target in newborn lung disease.

Figure 5. Fecal microbiota transfer alters the lung and gut microbiome of recipient mice. (*a*) Alpha and beta diversity of the gut fungal and (*b*) gut bacterial microbiome in 14-day-old neonatal mice. (*c*) Alpha and beta diversity of the lung microbiome. (*d*) Lung alpha and beta diversity of the bacterial microbiome. BPD_NO, BPD normoxia. BPD_HO, BPD hyperoxia. NoBPD_NO, NoBPD normoxia. NoBPD_HO, BPD hyperoxia. Ellipses indicate the 95% confidence interval.

Table 1. Cohort Clinical Characteristics and Demographics

	PPRD	BPD	P Value
n	64	38	
Gestational age (weeks)	29.0 (27.6 - 30.8)	25.7 (25 - 27.8)	< 0.001
Birthweight (g)	1145 (840 - 1330)	775 (670 - 860)	< 0.001
Female sex assigned at birth	37 (57.8%)	14 (36.8%)	0.041
Antenatal Steroids (No)	8 (17%)	4 (13.3%)	0.33
Surfactant (None)	27 (43.5%)	1 (2.6%)	<0.001
Apgar score (1 min)	6 (3 - 7)	4 (2 - 5)	< 0.001
Apgar score (5 min)	7 (6 - 8)	6 (5 - 7)	< 0.001
Small for gestational age*	6 (9.4%)	8 (21.1%)	0.098
Ceasarean section	28 (59.6%)	20 (66.7%)	0.531
Prolonged rupture of membranes‡	7 (15%)	5 (16.7%)	0.834
Critical Risk Index for Babies II (CRIB II) score	7 (4 - 9)	12 (9 - 14)	< 0.001
Antenatal antibiotic exposure	22 (46.8%)	15 (50%)	0.785
Duration of antenatal antibiotic exposure (d)	1 (0 - 1)	0 (0 - 1)	0.542
Postnatal antibiotic exposure	55 (85.9%)	38 (100%)	0.015
Duration of postnatal antibiotic exposure (d)	2 (1 - 2)	2 (1 - 4)	0.016
Respiratory Support on Day 3			
Mechanical ventilation	20 (37%)	33 (89.2%)	< 0.001
Fraction of inspired oxygen	0.21 (0.21 - 0.21)	0.25 (0.21 - 0.34)	< 0.001
Predicted risk of severe BPD[†]	4.40% (1.68 - 10.14%)	10.70% (8.73 - 14.49%)	< 0.001
Predicted risk of death[†]	2.84% (1.36 - 6.30%)	10.90% (7.69 - 16.00%)	< 0.001
Respiratory Support on Day 7			
Mechanical ventilation	15 (28.3%)	30 (83.4%)	< 0.001
Fraction of inspired oxygen	0.21 (0.21 - 0.23)	0.29 (0.24 - 0.30)	< 0.001
Predicted risk of severe BPD[†]	4.35% (1.54 - 9.40%)	11.09% (8.22 - 21.50%)	< 0.001
Predicted risk of death[†]	3.35% (1.1 - 5.52%)	10.21% (7.01 - 13.2%)	< 0.001
Endotracheal intubation	41 (66.1%)	37 (100%)	< 0.001
Ventilation duration (d)	1 (0 - 4)	34 (22 - 50)	< 0.001
Non-invasive ventilation duration (d)	5 (1 - 17)	14 (1 - 38)	0.053
Oxygen exposure duration (d)	13 (4 - 41)	92 (30 - 119)	< 0.001
Supplemental oxygen on day 28	23 (37.1%)	33 (91.7%)	<0.001
Death	0 (0%)	6 (15.8%)	< 0.001

Data are presented as median (interquartile range) or n (%) with significance testing by Mann-Whitney U or Pearson chi-squared test, as appropriate.
BPD, Bronchopulmonary dysplasia; PPRD, Post-prematurity respiratory disease. *< 3rd percentile, ‡ > 18 h, †NICHD Neonatal Outcomes Estimator

Author Contributions: Conceptualization: KW, NA, BP, SC, JP, AT. Clinical Sample and Data Collection: KW, MS, IM, EM, JD. Experimentation: KW, MS, AA, BH, KT, CW. Analysis: KW, IM, IK, OA, LT. Manuscript: KW. All authors have approved the final manuscript as submitted.

Funding: Research reported in this article was supported by the National Institutes of Health under award numbers K08 HL151907 (KW), L40 HL159581 (KW), KL2 TR3097 (VJ), K08 HL141652 (CVL), R01 HL156275 (NA), R01 HL129907 (NA), R21 DK129890K08 (JP), and R21 AI163503 (JP); the Dixon Fellowship (MS), the Microbiome Center of the University of Alabama at Birmingham (KW), and the Division of Neonatology at the University of Tennessee Health Science Center (AT).

Data Availability: Raw sequencing files are deposited at the National Center for Biotechnology Information Sequence Read Archive (BioProject: PRJNA982880). Processed data files are available at github.com/WillisLungLab/MiBPD

Disclosures: CL is the founder of ResBiotic Nutrition, Inc. and Alveolus Bio, Inc. KW and NA are advisors.

Inclusion and Diversity:

We support the inclusive, diverse, and equitable conduct of research. Multiple authors of this paper self-identify as underrepresented ethnic or gender minorities, or as a member of the LGBTQA+ community. While citing references scientifically relevant to this work, we also actively worked to promote gender balance in our reference list.

Acknowledgments:

We thank the infants, their parents, and the study coordinators, without whom this study would have been impossible. Confocal microscopy was performed at the UAB High-Resolution Imaging Facility with the assistance of Robert Grabski.

References

1. Lapcharoensap W, Lee HC, Nyberg A, Dukhovny D. Health Care and Societal Costs of Bronchopulmonary Dysplasia. Neoreviews 2018; 19: e211–e223.

2. Lui K, Lee SK, Kusuda S, Adams M, Vento M, Reichman B, Darlow BA, Lehtonen L, Modi N, Norman M, Håkansson S, Bassler D, Rusconi F, Lodha A, Yang J, Shah PS, Investigators IN for E of O (iNeo) of neonates. Trends in Outcomes for Neonates Born Very Preterm and Very Low Birth Weight in 11 High-Income Countries. The Journal of Pediatrics 2019; 215: 32-40.e14.

3. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. The Lancet 2006; 367: 1421–1431.

4. Thébaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, Aschner JL, Davis PG, McGrath-Morrow SA, Soll RF, Jobe AH. Bronchopulmonary dysplasia. Nat Rev Dis Primers 2019; 5: 78.

5. Dang AT, Marsland BJ. Microbes, metabolites, and the gut–lung axis. Mucosal Immunol 2019; 12: 843–850.

6. Willis KA, Stewart JD, Ambalavanan N. Recent advances in understanding the ecology of the lung microbiota and deciphering the gut-lung axis. Am J Physiol-lung C 2020; 319: L710–L716.

7. Stevens J, Steinmeyer S, Bonfield M, Peterson L, Wang T, Gray J, Lewkowich I, Xu Y, Du Y, Guo M, Wynn JL, Zacharias W, Salomonis N, Miller L, Chougnet C, O'Connor DH, Deshmukh H. The balance between protective and pathogenic immune responses to pneumonia in the neonatal lung is enforced by gut microbiota. Sci Transl Med 2022; 14.

8. Deshmukh HS, Liu Y, Menkiti OR, Mei J, Dai N, O'Leary CE, Oliver PM, Kolls JK, Weiser JN, Worthen GS. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. Nature Medicine 2014; 20: 524–530.

9. Bernardes E van T, Pettersen VK, Gutierrez MW, Laforest-Lapointe I, Jendzjowsky NG, Cavin J-B, Vicentini FA, Keenan CM, Ramay HR, Samara J, MacNaughton WK, Wilson RJA, Kelly MM, McCoy KD, Sharkey KA, Arrieta M-C. Intestinal fungi are causally implicated in microbiome assembly and immune development in mice. Nature Communications 2020; 11: 2577–16.

10. Arrieta M-C, Stiemsma LT, Dimitriu PA, Thorson L, Russell S, Yurist-Doutsch S, Kuzeljevic B, Gold MJ, Britton HM, Lefebvre DL, Subbarao P, Mandhane P, Becker A, McNagny KM, Sears MR, Kollmann T, Investigators CS, Mohn WW, Turvey SE, Finlay BB. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Science translational medicine 2015; 7: 307ra152-307ra152.

11. Tipton L, Müller CL, Kurtz ZD, Huang L, Kleerup E, Morris A, Bonneau R, Ghedin E. Fungi stabilize connectivity in the lung and skin microbial ecosystems. Microbiome 2018; 6: 12.

12. Higgins RD, Jobe AH, Koso-Thomas M, Bancalari E, Viscardi RM, Hartert TV, Ryan RM, Kallapur SG, Steinhorn RH, Konduri GG, Davis SD, Thebaud B, Clyman RI, Collaco JM, Martin CR, Woods JC, Finer NN, Raju TNK. Bronchopulmonary Dysplasia: Executive Summary of a Workshop. J Pediatrics 2018; 197: 300–308.

13. Cristea AI, Ren CL, Amin R, Eldredge LC, Levin JC, Majmudar PP, May AE, Rose RS, Tracy MC, Watters KF, Allen J, Austin ED, Cataletto ME, Collaco JM, Fleck RJ, Gelfand A, Hayes D, Jones MH, Kun SS, Mandell EW, McGrath-Morrow SA, Panitch HB, Popatia R, Rhein LM, Teper A, Woods JC, Iyer N, Baker CD. Outpatient Respiratory Management of Infants, Children, and Adolescents with Post-Prematurity Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline. Am J Resp Crit Care 2021; 204: e115–e133.

14. Staley C, Kaiser T, Beura LK, Hamilton MJ, Weingarden AR, Bobr A, Kang J, Masopust D, Sadowsky MJ, Khoruts A. Stable engraftment of human microbiota into mice with a single oral gavage following antibiotic conditioning. Microbiome 2017; 5: 87.

15. Chen X, Li P, Liu M, Zheng H, He Y, Chen M-X, Tang W, Yue X, Huang Y, Zhuang L, Wang Z, Zhong M, Ke G, Hu H, Feng Y, Chen Y, Yu Y, Zhou H, Huang L. Gut dysbiosis induces the development of pre-eclampsia through bacterial translocation. Gut 2020; : gutjnl-2019-319101.

16. Wrzosek L, Ciocan D, Borentain P, Spatz M, Puchois V, Hugot C, Ferrere G, Mayeur C, Perlemuter G, Cassard A-M. Transplantation of human microbiota into conventional mice durably reshapes the gut microbiota. Scientific reports 2018; 8: 6854.

17. Nardiello C, Mižíková I, Silva DM, Ruiz-Camp J, Mayer K, Vadász I, Herold S, Seeger W, Morty RE. Standardisation of oxygen exposure in the development of mouse models for bronchopulmonary dysplasia. Disease models & mechanisms 2017; 10: 185–196.

18. Willis KA, Siefker DT, Aziz MM, White CT, Mussarat N, Gomes CK, Bajwa A, Pierre JF, Cormier SA, Talati AJ. Perinatal maternal antibiotic exposure augments lung injury in offspring in experimental bronchopulmonary dysplasia. American Journal of Physiology - Lung Cellular and Molecular Physiology 2019; 3: 21.

19. Baker JM, Hinkle KJ, McDonald RA, Brown CA, Falkowski NR, Huffnagle GB, Dickson RP. Whole lung tissue is the preferred sampling method for amplicon-based characterization of murine lung microbiota. Microbiome 2021; 9: 99.

20. Pierre JF, Phillips GJ, Chandra LC, Rendina DN, Thomas-Gosain NF, Lubach GR, Lyte M, Coe CL, Gosain A. Lyticase Facilitates Mycobiome Resolution Without Disrupting Microbiome Fidelity in Primates. J Surg Res 2021; 267: 336–341.

21. Willis KA, Purvis JH, Myers ED, Aziz MM, Karabayir I, Gomes CK, Peters BM, Akbilgic O, Talati AJ, Pierre JF. Fungi form interkingdom microbial communities in the primordial human gut that develop with gestational age. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2019; 33: 12825–12837.

22. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ, Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, Brejnrod A, Brislawn CJ, Brown CT, Callahan BJ, Caraballo-Rodríguez AM, Chase J, Cope EK, Silva RD, Diener C, Dorrestein PC, Douglas GM, Durall

DM, Duvallet C, Edwardson CF, Ernst M, Estaki M, Fouquier J, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol 2019; 37: 852–857.

23. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. Nature methods 2016; 13: 581–583.

24. Smirnova E, Huzurbazar S, Jafari F. PERFect: PERmutation Filtering test for microbiome data. Biostatistics 2018; 20: 615–631.

25. Greenberg RG, McDonald SA, Laughon MM, Tanaka D, Jensen E, Meurs KV, Eichenwald E, Brumbaugh JE, Duncan A, Walsh M, Das A, Cotten CM, Network EKSNI of CH and HDNR. Online clinical tool to estimate risk of bronchopulmonary dysplasia in extremely preterm infants. Archives Dis Child - Fetal Neonatal Ed 2022; 107: 638–643.

26. Laughon MM, Langer JC, Bose CL, Smith PB, Ambalavanan N, Kennedy KA, Stoll BJ, Buchter S, Laptook AR, Ehrenkranz RA, Cotten CM, Wilson-Costello DE, Shankaran S, Meurs KPV, Davis AS, Gantz MG, Finer NN, Yoder BA, Faix RG, Carlo WA, Schibler KR, Newman NS, Rich W, Das A, Higgins RD, Walsh MC, Network EKSNI of CH and HDNR. Prediction of Bronchopulmonary Dysplasia by Postnatal Age in Extremely Premature Infants. Am J Resp Crit Care 2011; 183: 1715–1722.

27. Cantu A, Gutierrez MC, Dong X, Leek C, Sajti E, Lingappan K. Remarkable sex-specific differences at Single-Cell Resolution in Neonatal Hyperoxic Lung Injury. Am J Physiol-lung C 2022; .

28. Trembath A, Laughon MM. Predictors of Bronchopulmonary Dysplasia. Clinics in perinatology 2012; 39: 585–601.

29. Laforest-Lapointe I, Arrieta M-C. Microbial Eukaryotes: a Missing Link in Gut Microbiome Studies. Msystems 2018; 3: e00201-17.

30. Bongers KS, Chanderraj R, Woods RJ, McDonald RA, Adame MD, Falkowski NR, Brown CA, Baker JM, Winner KM, Fergle DJ, Hinkle KJ, Standke AK, Vendrov KC, Young VB, Stringer KA, Sjoding MW, Dickson RP. The Gut Microbiome Modulates Body Temperature Both in Sepsis and Health. Am J Resp Crit Care 2022; .

31. Moutsoglou DM, Tatah J, Prisco SZ, Prins KW, Staley C, Lopez S, Blake M, Teigen L, Kazmirczak F, Weir EK, Kabage AJ, Guan W, Khoruts A, Thenappan T. Pulmonary Arterial Hypertension Patients Have a Proinflammatory Gut Microbiome and Altered Circulating Microbial Metabolites. Am J Resp Crit Care 2022; .

32. Tashiro H, Shore SA. The Gut Microbiome and Ozone-induced Airway Hyperresponsiveness. Mechanisms and Therapeutic Prospects. Am J Resp Cell Mol 2021; 64: 283–291.

33. Wang Z, Locantore N, Haldar K, Ramsheh MY, Beech AS, Ma W, Brown JR, Tal-Singer R, Barer MR, Bafadhel M, Donaldson GC, Wedzicha JA, Singh D, Wilkinson TMA, Miller BE, Brightling CE. Inflammatory Endotype–associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. Am J Resp Crit Care 2021; 203: 1488–1502.

34. Dickson RP, Schultz MJ, Poll T van der, Schouten LR, Falkowski NR, Luth JE, Sjoding MW, Brown CA, Chanderraj R, Huffnagle GB, Bos LDJ, Beer FM de, Bos LD, Claushuis TA, Glas GJ, Horn J, Hoogendijk AJ, Hooijdonk RT van, Huson MA, Jong MD de, Juffermans NP, Lagrand WA, Poll T van der, Scicluna B, Schouten LR, Schultz MJ, Sluijs KF van der, Straat M, Vught LA van, Wieske L, et al. Lung

Microbiota Predict Clinical Outcomes in Critically Ill Patients. Am J Resp Crit Care 2020; 201: 555–563.

35. O'Dwyer DN, Ashley SL, Gurczynski SJ, Xia M, Wilke C, Falkowski NR, Norman KC, Arnold KB, Huffnagle GB, Salisbury ML, Han MK, Flaherty KR, White ES, Martinez FJ, Erb-Downward JR, Murray S, Moore BB, Dickson RP. Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis. Am J Resp Crit Care 2019; 199: 1127–1138.

36. Ashley SL, Sjoding MW, Popova AP, Cui TX, Hoostal MJ, Schmidt TM, Branton WR, Dieterle MG, Falkowski NR, Baker JM, Hinkle KJ, Konopka KE, Erb-Downward JR, Huffnagle GB, Dickson RP. Lung and gut microbiota are altered by hyperoxia and contribute to oxygen-induced lung injury in mice. Science translational medicine 2020; 12: eaau9959.

37. Dickson RP, Singer BH, Newstead MW, Falkowski NR, Erb-Downward JR, Standiford TJ, Huffnagle GB. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nat Microbiol 2016; 1: 16113.

38. Combs MP, Wheeler DS, Luth JE, Falkowski NR, Walker NM, Erb-Downward JR, Lama VN, Dickson RP. Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study. Lancet Respir Medicine 2021; 9: 601–612.

39. Alcazar CG-M, Paes VM, Shao Y, Oesser C, Miltz A, Lawley TD, Brocklehurst P, Rodger A, Field N. The association between early-life gut microbiota and childhood respiratory diseases: a systematic review. Lancet Microbe 2022; 3: e867–e880.

40. Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M, Kirpalani H, Laughon MM, Poindexter BB, Duncan AF, Yoder BA, Eichenwald EC, DeMauro SB. The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. American Journal of Respiratory and Critical Care Medicine 2019; 200: 751–759.

41. Xia S, Ellis LV, Winkley K, Menden H, Mabry SM, Venkatraman A, Louiselle D, Gibson M, Grundberg E, Chen J, Sampath V. Neonatal hyperoxia induces activated pulmonary cellular states and sex-dependent transcriptomic changes in a model of experimental bronchopulmonary dysplasia. Am J Physiol-lung C 2022; .

42. Lao JC, Bui CB, Pang MA, Cho SX, Rudloff I, Elgass K, Schröder J, Maksimenko A, Mangan NE, Starkey MR, Skuza EM, Sun YBY, Beker F, Collins CL, Kamlin OF, König K, Malhotra A, Tan K, Theda C, Young MJ, McLean CA, Wilson NJ, Sehgal A, Hansbro PM, Pearson JT, Polo JM, Veldman A, Berger PJ, Nold-Petry CA, Nold MF. Type 2 immune polarization is associated with cardiopulmonary disease in preterm infants. Sci Transl Med 2022; 14: eaaz8454.

43. Hurskainen M, Mižíková I, Cook DP, Andersson N, Cyr-Depauw C, Lesage F, Helle E, Renesme L, Jankov RP, Heikinheimo M, Vanderhyden BC, Thébaud B. Single cell transcriptomic analysis of murine lung development on hyperoxia-induced damage. Nat Commun 2021; 12: 1565.

44. Zaneveld JR, McMinds R, Thurber RV. Stress and stability: applying the Anna Karenina principle to animal microbiomes. Nat Microbiol 2017; 2: 17121.

45. Lal CV, Ambalavanan N. Biomarkers, Early Diagnosis, and Clinical Predictors of Bronchopulmonary Dysplasia. Clinics in perinatology 2015; 42: 739–754.

46. Gallacher D, Mitchell E, Alber D, Wach R, Klein N, Marchesi JR, Kotecha S. Dissimilarity of the gut-lung axis and dysbiosis of the lower airways in ventilated preterm infants. The European Respiratory

Journal 2020; : 1901909.

47. Underhill DM, Iliev ID. The mycobiota: interactions between commensal fungi and the host immune system. Nat Rev Immunol 2014; 14: 405–416.

48. Jiang TT, Shao T-Y, Ang WXG, Kinder JM, Turner LH, Pham G, Whitt J, Alenghat T, Way SS. Commensal Fungi Recapitulate the Protective Benefits of Intestinal Bacteria. Cell host & microbe 2017; 22: 809-816.e4.

The fungal intestinal microbiota predict the development of bronchopulmonary dysplasia

Kent A. Willis, Mary Silverberg, Isaac Martin, Ahmed Abdelgawad, Kosuke Tanaka, Ibrahim Karabayir, Brian A. Halloran, Erin D. Myers, Jay P. Desai, Catrina T. White, Charitharth V. Lal, Namasivayam Ambalavanan, Brian M. Peters, Viral Jain, Oguz Akbilgic, Laura Tipton, Tamás Jilling, Stephania A. Cormier, Joseph F. Pierre, Ajay J. Talati

ONLINE DATA SUPPLEMENT

Key Resource Table

Reagent	Company - Catalog #	RRID
Teklad S-2335 Mouse Breeder Sterilizable Diet	Envigo - 7904.15	
Penicillin VK	Thermo Fisher Scientific (TFS)-AC455230050	
Cefoperazone Sodium	TFS - AAJ6518506	
Clindamycin Sodium	TFS - 1G 11-101-3689	
Polyethylene glycol 3350 (Miralax)	TFS - J61495.AK	
Ertapenem Sodium	Fisher - 50-997-777 5G	
Vancomycin HCL	Milipore Sigma - 1404-93-9	
Neomycin Sodium	TFS - 50-186-3466	
Fecal Microbiota Transplant	This study only	
Lamina Propria Isolation Kit, Mouse	Miltenyi Biotec - 130-097-410	

Hank's Balanced Salt Solution	TFS - 14170112 or 14025092	
DNase I	Sigma - D5025	
Collagenase, Type I	Invitrogen - 7100017	
Fetal Bovine Serum	Millipore Sigma - F2442-500ML	
C-Tube	Miltenyi Biotec - 130-096-334	
RBC lysis buffer	Biolegend - 420301	
IC Fixation Buffer	TFS - 00-8222-49	
Permeabilization Buffer	TFS - 00-8333-56	
VMR Cell Strainers, 40, 70 μm	Avantor - 76327-098	
V-bottom, 96 well plate	Greiner Bio-One - 651901	
Sabouraud Dextrose Broth 4% (pH 5.6)	TFS - R064416	
zymoBIOMICS microbial community standards	Zymo Research - D6300 and D6310	
zymoBIOMICS microbial community DNA standards	Zymo Research - D6305/6306 and D6311	
zymoBIOMICS spike-in control I	Zymo Research - D6320-10	
zymoBIOMICS spike-in control II	Zymo Research - D6321-10	

zymoBIOMICS gut microbiome standard	Zymo Research - D6331	
RNase-free DNase Set	Qiagen - 79254	
QIAshredder	Qiagen - 79656	
PrimeScript RT Master Mix	Takara Biosciences - RR036B	
Bioanalyzer High Sensitivity DNA Analysis Kit	Agilent Technologies - 5067-4626	
Tissue Protein Extraction Reagent	Pierce Biotechnology - 78510	
Roche Complete Protease Inhibitor	Milipore Sigma - 11836153001	
Bradford Protein Assay Kit I	Bio-Rad - 5000001	
Protein Assay Standard I	Bio-Rad - 5000005	
Immun-Star™ WesternC™ Chemiluminescence Kit	Bio-Rad - 170-5070	
Paraformaldehyde, 4% w/v aq. soln.	TFS - 047392.9M	
Antigen Retrieval Buffer	Abcam - ab93678	
ProLong Diamond Anti-Fade Mounting Media with DAPI	TFS - P36962	RRID:AB_2307445
ArC™ Amine Reactive Compensation Bead Kit	Invitrogen - A10346	

UltraComp eBeads	Invitrogen - 01-2222-41	
Antibodies		
Ghost Dye Violet 510	TonboBio - 13-0870-T100	
LIVE/DEAD Fixable Blue Dead Cell Stain Kit, for UV removal	Invitrogen - L23105	
Mouse BD Fc Block (CD16/32)	BD Biosciences - 553142	RRID:AB_394656
Ly-6-G Pacific Blue™	Biolegend - 127611	RRID:AB_1877212
MERTK (Mer) BV 711	Biolegend - 151515	RRID:AB_2876505
CD64 (FcγRI) FITC	Biolegend - 139315	RRID:AB_2566555
F4/80 BUV737	BD Biosciences - 749283	RRID:AB_2873658
Ly-6C Brilliant Violet 605™	Biolegend - 128035	RRID:AB_2562352
CD11c - BV650	Biolegend - 117339	RRID:AB_2562414
CD169 (Siglec-1) APC	Biolegend - 142417	RRID:AB_2565640
CX3CR1 Recombinant PE	Biolegend - 153705	RRID:AB_2734221
CD170 (Siglec-F) - BV421	Biolegend - 155509	RRID:AB_2810421
CD3ε (17A2) violetFluor™ 450	TonboBio - 75-0032	RRID:AB_2621923
CD3ε BUV 737	BD - 612771	RRID:AB_2870100
CD19 Pacific Blue™	Biolegend - 115526	RRID:AB_493341

CD11b Pacific Blue™	Biolegend - 101224	RRID:AB_755986
CD49b (pan-NK cells) Pacific Blue™	Biolegend - 108918	RRID:AB_2265144
F4/80 Pacific Blue™	Biolegend - 123123	RRID:AB_893487
FcεRIα Pacific Blue™	Biolegend - 134313	RRID:AB_10612933
CD90.2 (Thy1.2) FITC	Biolegend - 105306	RRID:AB_313177
CD127 (IL-7Rα) APC	Biolegend - 135012	RRID:AB_1937216
CD45 APC/Cyanine7	Biolegend - 103116	RRID:AB_312981
IL-33R (ST2) (RMST2-33), PE	TFS - 12-9333-82	RRID:AB_2572706
RORγt, PerCP-Cy™5.5	BD Biosciences - 562683	RRID:AB_2737720
GATA3, PE-Cy™7	BD Biosciences - 560405	RRID:AB_1645544
αSMA Monoclonal Anti-mouse, IgG	Abcam - ab7817	RRID:AB_262054
von Willebrand Factor (vWF), Polyclonal Rabbit Anti-mouse, IgG	TFS, Invitrogen - PA5-16634	RRID:AB_10982615
CD169 (Siglec1), Clone 3D6.112, Monoclonal Rabbit Anti-mouse, IgG	Novus Biologicals - NBP3-08989-0.1mg	RRID:AB_2923219
CD11c Monoclonal Armenian Hamster Anti-mouse, IgG	TFS, Invitrogen - 14-0114-82	RRID:AB_467115

F4/80 Purified anti-mouse Antibody	Biolegend - 123102	RRID:AB_893506
Alexa Fluor™ 488 Tyramide SuperBoost™ Kit, goat anti-rabbit IgG	TFS - B40922	
Alexa Fluor™ 647 Tyramide SuperBoost™ Kit, goat anti-mouse IgG	TFS - B40916	
Goat anti-Hamster IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 647	TFS, Invitrogen - A-21451	RRID:AB_2535868
Goat anti-Rat IgG - Alexa Fluor™ 555	Invitrogen - A-21434	RRID:AB_2535855
Chicken anti-Mouse IgG - AF™ 647	Invitrogen- A-21463	RRID:AB_2535869
Goat anti-Rabbit IgG - AF™ 555	Invitrogen- A-21428	RRID:AB_2535849
Goat anti-Hamster IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 647	TFS, Invitrogen - A-21451	RRID:AB_2535868
Goat anti-rabbit-HRP antibody	Cell Signaling - 7074	RRID:AB_2099233
Donkey anti-goat-HRP antibody	SouthernBiotech - 6402	RRID:AB_2796335
Primer Sequences		

Bacterial 16S, V4-V5, 450 bp	515F	GTGCCAGCGCCGCGGTAA
	907R	CCGTCAATTCCTTTGAGTTT
Fungal, ITS1, 200-400 bp	ITS5-1737F	GGAAGTAAAAGTCGTAACAAGG
	ITS2-2043R	GCTGCGTTCTTCATCGATGC
Fungal, ITS2, 380 bp	ITS3-2024F	GCATCGATGAAGAACGCAGC
	ITS4-2409R	TCCTCCGCTTATTGATATGCTCCTCCGCTTATT GATATGC
Organisms		
C57Bl/6J mouse	Jackson Laboratory - 000664	RRID:IMSR_JAX:000664
Equipment		
Luminex 200 System	Merck Millipore	RRID:SCR_018025
ProOx 360 controller	BioSpherix	RRID:SCR_021130
gentleMACS	Miltenyi Biotec	RRID:SCR_020271
FACS Symphony A5 SE	BD Biosciences	RRID:SCR_022674
A1R HD confocal microscope	Nikon	RRID:SCR_020317
flexiVent	SCIREQ	RRID:SCR_022673
Vevo 770 High-Resolution *in vivo* Micro-Imaging System	Fujifilm VisualSonics	RRID:SCR_022921
2100 Bioanalyzer Instrument	Agilent	RRID:SCR_018043
QuantStudio 6	Applied Biosciences	RRID:SCR_020239
Rotor-Gene Q Series	Qiagen	RRID:SCR_018976

NovoSeq 6000 system	Illumina	RRID:SCR_016387
MiSeq platform	Illumina	RRID:SCR_020133
HiSeq 4000 platform	Illumina	RRID:SCR_016386
Software		
NICHD Neonatal Outcomes Estimator	https://neonatal.rti.org	
FACSDiva	BD Biosciences - v9.0	RRID:SCR_001456
FlowJo for Mac	BD Biosciences - v10.8.1	RRID:SCR_008520
Rotor-Gene Q Series Software	Qiagen	RRID:SCR_015740
FIJI	https://fiji.sc	RRID:SCR_002285
Prism 9 for Mac	GraphPad - v9.4.1	RRID:SCR_002798
SPSS Statistics	IBM - 28.0.1	RRID:SCR_002865
R	R project for statistical computing - 4.2.2	RRID:SCR_001905
RStudio	Posit - 2022.12.0	RRID:SCR_000432
phyloseq	1.42.0	RRID:SCR_013080
vegan	2.6-4	RRID:SCR_011950
DESeq2	v1.38.2	RRID:SCR_015687
mia	1.6.0	RRID:SCR_023619
SpiecEasi	1.1.2	RRID:SCR_022712
igraph	1.4.1	RRID:SCR_019225
caret	6.0-94	RRID:SCR_021138
D2 calculator	https://github.com/jamescarson3/computeD2	
QIIME 2	2022.11	RRID:SCR_021258
DADA2	v1.26	RRID:SCR_023519

PERFect	0.2.4	RRID:
SILVA	138.1	RRID:SCR_006423
UNITE	9.0	RRID:SCR_006518
NCBI MOLE-BLAST		RRID:SCR_004870
CLC Genomic Workbench	Qiagen - v22	RRID:SCR_011853
ClustVis	https://biit.cs.ut.ee/clustvis/	RRID:SCR_017133
Ingenuity Pathway Analysis	Qiagen (July 2022 edition)	RRID:SCR_008653
Datasets		
RNAseq, Mouse	This paper	
RNAseq, hBECs	This paper	
16S, human	This paper	
16S, mouse	This paper	
ITS2, human	This paper	
ITS2, mouse	This paper	

Resource Availability

Lead Contact: Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Kent Willis (kawillis@uab.edu).

Materials Availability: This study did not generate any unique reagents or transgenic animals.

Data Availability:
- Raw RNA-seq, 16S and ITS2 sequencing data are deposited at the NCBI Sequence Read Archive (Access Number: PRJNA982880).
- Processed data files and original code are available at github.com/WillisLungLab/MiBPD.
- Any additional data required to reanalyze the data presented in this paper are available from the lead contact upon request.

Experimental Model and Subject Details

Study Subjects:
University of Tennessee Health Science Center cohort: This study was approved by the Institutional Review Board of The University of Tennessee under protocol 17-05311-XP and

conducted in accordance with the Declaration of Helsinki. We performed a prospective observational cohort study at the regional NICU at Regional One Health (Memphis, TN, USA) from July 2017-January 2020, pre-registered with clinicaltrials.gov (NCT03229967). The Microbial Influence on the Development of Bronchopulmonary Dysplasia (MiBPD) study approached the mothers of all inborn very low birthweight infants (VLBW, < 1500g) without known major congenital anomalies or immunodeficiency for potential consent for enrollment during the first week of life unless they were enrolled in a concurrent trial of probiotics that enrolled < 10 infants during this period. Mothers provided written consent on behalf of themselves and assent for the inclusion of their newborn prior to enrollment. Samples were collected weekly for the first month of life. Meconium samples collected within the first 72 hours have been described[1]. Analysis in this study was constrained to fecal samples collected during the second week of life. Demographic and clinical data were collected to describe the clinical course and to identify the severity of bronchopulmonary dysplasia (BPD) according to the NICHD workshop definition [2]. The risk of developing BPD was predicted using the NICHD Neonatal BPD Outcomes Estimator (neonatal.rti.org, 2022 updated formula)[3]. Human subjects data is reported in accordance with the extended STROBE guidelines [4].

University of Alabama at Birmingham cohort: This study was approved under protocol IRB-300003994 by the IRB at the University of Alabama at Birmingham (UAB, Birmingham, AL, USA). Samples from this cohort were collected in oxygen-reduced PBS immediately prior to FMT to the mice. The samples were used for the generation of the pseudohumanized mouse model and were collected from August 2021 to June 2022.

Animals:
Animal experiments were performed at UAB under IACUC protocol 22042. 8-week-old female C57Bl/6J mice (Stock Number 000664, RRID:IMSR_JAX:000664) were purchased from the Jackson Laboratory and allowed to acclimate in specific-pathogen free housing with 4 animals per cage, on a 12-hour light/dark cycle, at 20-24C, with *ad libitum* access to irradiated rodent chow (Teklad 7904, Envigo) in the vivarium at the UAB for two weeks. Animal studies were performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health under protocol 22042, approved by the Institutional Animal Care and Use Committee at UAB. Animal experimentation is reported in accordance with the ARRIVE guidelines [5].

Generation of pseudo-humanized mice:
Pseudo-humanized mice were generated by fecal microbiota transplant (FMT) from human infant donors with or without severe BPD, following antibiotic preconditioning, as previously described [6–8], generating mice we named NoBPD-FMT and BPD-FMT, respectively. Briefly, 9-week-old dams were subjected to antibiotic administration for two weeks in their drinking water, which they were allowed to access *ad libitum*. The first week consisted of systemically absorbable antibiotics: penicillin VK, cefoperazone sodium, and clindamycin sodium (all at a concentration of 1mg/mL). This was followed by a bowel cleansing regimen by oral-gastric gavage with 200 uL of polyethylene glycol 3350 at 425 g/L. This was repeated twice. Mice were placed on the second week of antibiotic therapy in the drinking water, which consisted of the non-absorbable antibiotics ertapenem sodium, vancomycin sodium, and neomycin sodium (all at a concentration of 1mg/mL). Cage bottoms were changed daily and after each gavage of polyethylene glycol, as mice are coprophagous and could reinoculate themselves with stool. After two weeks of antibiotic treatment, female mice were given stool from neonatal human donors with or without BPD. The stool was preserved in oxygen-reduced sterile PBS. We then performed FMT. Mice in each group were gavaged twice with 200 uL of sample from the same human donor. Stool samples were collected after antibiotic therapy, after FMT engraftment, or at

the time of harvest. After engraftment, dams inoculated with the same donors FMT were bred simultaneously to generate neonatal mice for further experimentation. On day 2 after birth, the pups were inoculated with the same donor FMT to create BPD-FMT and NoBPD-FMT mice, respectively. Each experiment was conducted with at least two litters arising from the same human donor and a minimum of three human donors in each experimental group (6 litters=3 donors/group).

Neonatal hyperoxia exposure model:
We utilized our established, standardized hyperoxia-exposure model of BPD [9, 10]. We time-mated the mice to produce multiple simultaneous birth cohorts with the same perinatal exposure. On the day of birth, pups from two consecutively born litters with the same perinatal exposure were pooled, and the pups were re-distributed evenly between the two dams. Litter sizes for all experiments were adjusted to 5–8 pups per treatment group to minimize nutritional effects on lung development. One pooled litter was randomly assigned to hyperoxia [fraction of inspired oxygen (FiO$_2$) 0.85]) and the other to air (FiO$_2$ 0.21). Pups were exposed continuously for 11 days, starting on the third day after birth (P3-14). Oxygen concentrations were maintained using a ProOx monitor (Biospherix). Dams were rotated daily between the two pooled litters to limit the complications of hyperoxia. Growth was monitored daily for all pups throughout the experiment.

Method Details

Data collection:
Clinical data were collected from the medical record that described clinical illness severity, infant characteristics, maternal and infant demographics, the extent of prematurity, respiratory parameters, and known microbiome modulators when the infant reached 36 weeks' corrected gestational age or was discharged. BPD was adjudicated at 36 weeks corrected gestational age using the NICHD workshop definition [2]. We quantified clinical illness severity with the Critical Risk Index for Babies II (CRIB II)[11]. The risk of developing BPD was predicted using the NICHD Neonatal BPD Outcomes Estimator (neonatal.rti.org, 2022 updated formula)[3].

Patient and public involvement:
Neither patients nor the public were involved in designing this research study.

RNA-seq:
Bulk RNA-seq was performed on isolated tissue from the left middle lobe using established methods [12]. Briefly, 25 mg of tissue was collected in RLT buffer (Qiagen) with 1% (v/v) 2-Mercaptoethanol (BME, Sigma Aldrich), homogenized using a QIAshredder (Qiagen), and isolated with an RNeasy Kit (Qiagen) with on-column removal of DNase. DNA purity and concentration were validated with the Bioanalyzer High Sensitivity DNA Analysis chip (Agilent Technologies) at the Heflin Genomics Core Facility. Samples were sent to Novogene for RNA library preparation and transcriptome sequencing on the HiSeq 2500 platform (Illumina) using a 150-nucleotide paired-end read length [12].

FlexiVent pulmonary function testing:
The P14 mice used for this analysis were not used for other analyses. Forced oscillometry was performed as described [13, 14]. Briefly, we performed a tracheostomy on the sedated mice with the appropriate cannula and secured it with two 3-0 sutures. We performed the neonatal pulmonary function assessment program on the flexiVent system (SCIREQ). We calibrated the system with the tracheal cannula prior to each mouse.

Histology and immunohistochemistry:
We gravity inflated the right lung of each mouse to 20 cm H_2O with 4% formalin (Thermo Fisher Scientific), and were placed into 100% ethanol within 16 h. After paraffin embedding, we cut 4-5 m slides at 3 random levels through the block that were stained with hematoxylin and eosin for morphometry. At each level, three slides were made from adjacent sections for immunohistochemistry. These slides were deparaffinized and rehydrated with graduated concentrations of ethanol. We performed antigen retrieval with heated 10 µM Sodium Citrate Buffer with 20% Tween. Slides were fenestrated, blocked in 1% BSA and anti-CD16/32 (BD Biosciences) for 30 min, then incubated overnight with either anti-vWF and or anti-αSMA at 4C in incubation buffer (1% BSA, 1% normal donkey serum, 0.3% Triton X-100, and 0.01% sodium azide in PBS). The next day, they were washed in PBS, blocked again, counterstained with the appropriate secondary antibodies, washed, and finally counterstained with ProLong Diamond Anti-Fade Mounting Media with DAPI (Thermofisher Scientific). Images were captured using an A1R HD inverted confocal microscope (Nikon).

Bacterial and fungal microbiota analysis:
The first non-transitional stool sample collected during the second week of life was used to assess the human gut microbiota. In mice, liquid nitrogen snap-frozen homogenized whole left lung or a 1 cm section of terminal ileum were used because of the advantages in quantifying the adherent mucosal microbiota [15]. We used ZymoBIOMICS whole organism and DNA microbial community standards (Zymo Research) as well as sterile-filtered PBS to create pairs of positive and negative controls appropriate for each step of the sample collection and isolation procedure. Microbial DNA was extracted using the ZymoBIOMICS DNA Miniprep Kit (Zymo Research) with the addition of a lyticase (200 Units per 1 mL sample volume) predigestion with 10-minute bead bashing on a Fisher Vortex Genie 2 (Thermo Fisher Scientific) at RT, then 37 C with gentle agitation for 20 min, as previously validated to facilitate extraction of fungal DNA [16]. Extracted DNA was sequenced using the MiSeq platform (Illumina) at Novogene (human samples) or Argonne National Laboratory (mouse samples) using 16S V3-4 (bacterial) rRNA with primers 515F-806R and the internal transcribed spacer (ITS) 2 (fungal) rRNA gene primers. Primer design was chosen based on prior published optimization for mycobiome amplification in respiratory samples [17, 18]. Quantitative RT-PCR of the ITS1, ITS2, and 16S genes was performed as described [19], using TaqMan probes (Thermo Fisher Scientific) validated with ZymoBIOMICS controls (Zymo Research) and additional human and mouse samples. QC was performed at the UAB Genomics Core.

Bioinformatics:
Microbiomics - We used QIIME 2 [20] to import and trim ITS2 and 16S rRNA gene amplicon sequences. DADA2 [21] was used to denoise and cluster amplicon sequence variants (ASVs). ASV taxonomy was assigned with the RDP naive Bayesian Classifier using the SILVA 138.1 and UNITE 9.0 databases, for bacteria and fungi, respectively. All ASVs aligning to the division Chytridiomycota or unassigned at the phylum level were then removed because confirmatory analysis with BLAST revealed these sequences to be either host mitochondrial or plant material contaminates. Contamination source modeling was then performed using the R package *PERFect* [22], using permutation filtering with p-value ordering, at an alpha value of 0.05. Decontaminated ASV tables were then exported into R where they were normalized, transformed, and analyzed with the following packages: *vegan*, *phyloseq*, *DESeq2*, *SpiecEasi* (Sparse Inverse Covariance Estimation for Ecological Association Inference), *tidyverse, igraph, mia,* and *caret*. Alpha diversity was quantified with the Shannon and Simpson Indices. We displayed beta diversity with both principal components analysis of Euclidean distances and principal coordinates analysis of Bray-Curtis dissimilarity matrices. Significance testing was performed using PERMANOVA, and evaluated confounding by differential dispersion using

PERMDISP. Feature selection was performed using DESeq2 and Random Forest using *ranger* and *caret*. Unsupervised clustering was performed using Dirichlet-Multinomial Mixture modeling using the packages *mia* and *DirichletMultinomial*. Feature selection was performed using the *fitted* function within *DirichletMultinomial*. Mapping of clinical data to DMM clusters was performed using Canonical Correspondence Analysis (CCA) using the *vegan* package.

RNAseq - Raw sequencing data was aligned, processed and normalized, then differential gene expression was calculated using the CLC Genomic Workbench (Qiagen). Genes with adjusted p-value (q) < 0.05 and log(FoldChange) > 0.301 were considered differentially expressed. Heatmaps and principal components analyses were graphed using ClustVis. Differentially expressed genes were input into Ingenuity IPA (Qiagen) to identify significantly regulated networks and pathways.

Machine learning models:
Gradient boosting algorithms utilize a group of shallow trees and assemble them into a single prediction score to improve their predictive properties [23]. We developed a Light Gradient Boosted Machine (LightGBM) [24] model to predict BPD using both clinical demographics at birth and the corresponding microbiome data. Clinical parameters were curated from those previously validated in the Neonatal BPD Outcome Predictor [3], and included gestational age at birth, maternal-self-reported race, birth weight, temperature on admission to the NICU, and mode of ventilation. Since the sample size of the dataset is modest in comparison to the number of unique variables in the microbiota data, we only utilized the kingdom and phylum-level microbiota data to maintain generalizability and reduce the risk of over-fitting. To construct the model, we split the dataset into two sets: 80% into a model-building discovery set and 20% as a holdout validation set. We used 5-fold cross-validation in the discovery set to tune the hyperparameters of the algorithm. We then assessed the accuracy of the training phase using the validation set. A Bayesian algorithm [25] was chosen for hyperparameter tuning. To tune the model, we adjusted the number of trees, feature fraction, learning rate, and the maximum depth of the trees. In addition, the training phase was stopped if there was no consecutive improvement in the validation set. Finally, the LightGBM model from the cross-validation was performed on the holdout set, and we calculated the resulting AUC of the ensemble model.

We also implemented the default variable importance analysis of the LightGBM algorithm to evaluate the contribution of the variables into models, in which their contribution was weighted over folds according to the model's performance on the corresponding validation set. We also evaluated the directional effect of the variables on the BPD risk prediction score within a 95% confidence interval (inverse or direct relationship) by systematically increasing by one unit for categorical variables and one standard deviation for continuous variables.

Statistical analysis: Descriptive statistical analysis of the human data was performed in SPSS Statistics (IBM). Murine data was analyzed primarily in R and Prism 9 (GraphPad, Inc.).

Supplemental Information

Extended Data:

The fungal microbiota predicts BPD development:
To test the predictive potential of the mycobiota, we first developed random forest machine-learning models using fungal or bacterial microbiome as exploratory analyses (supplemental figure S4). The fungal model (supplemental figure S4a-b), which had an area under the receiver operating curve of 0.71, identified several rare fungal genera, such as *Penicillium*, *Gamszarea*,

and *Verticillium* as the most discriminatory taxa. In the bacterial model, which had a receiver operating curve of only 0.58, *Enterococcus* and *Acinitobacter* were the most discriminatory taxa (supplemental figure S3c-d).

Distinct fungal community clusters are linked to clinical outcomes:
Having shown that fungal microbiota features are associated with BPD development, we sought to identify other clinical characteristics that may contribute to heterogeneity in the composition of the neonatal mycobiome. First, we used PERMANOVA to screen potential additional contributors to fungal community composition. Of the potential fungal microbiome covariates we examined none remained significant after adjustment for false discovery (supplemental table S3, figure S6). When we tested potential bacterial covariates we made similar observations (supplemental table S4).

Heterogeneity in the mycobiome:
We next used unsupervised clustering to explore heterogeneity in fungal community features using Dirichlet-Multinomial Mixtures (DMM) modeling [26] (supplemental figure S8). In contrast to our previous approach, this method identifies clusters based on their microbial composition, which can then be associated with clinical characteristics. This permits the identification of microbial heterogeneity within disease states that can go otherwise undetected. In this study, Laplace analysis for the whole mycobiome identified 5 clusters as the optimal fit point (supplemental figure S9a). Membership in Cluster 1 of the fungal DMM model (supplemental figure S8a-c) was driven by the relative abundance of an *Aureobasidium* ASV and a *Saccharomyces* ASV (supplemental figure S9b). Membership in Cluster 2 was driven by a *Candida* ASV (supplemental figure S9b). Cluster 3 was driven primarily by an *Aureobasidium* ASV. Cluster 4 was driven by *Candida* and *Aureobasidium* ASVs and to a lesser extent by an *Issatchenkia* ASV. Finally, Cluster 5 was almost entirely driven by a *Candida* ASV. We then used canonical correspondence analysis (CCA) to map clinical characteristics that may be associated with the fungal composition profiles identified by the DMM components (supplemental figure S9c). Clusters 1 and 3 shared similar vectors and were closely associated with BPD and increased illness severity (CRIB-II). Cluster 2 was in opposition, and therefore associated with opposing markers of illness severity such as increasing gestational age (GA), birthweight (BW) and male sex-assigned at birth (AMAB). The limited number of samples in Cluster 5 were at right angles to the majority of these clinical variables and were associated with low fungal evenness (arbitrarily defined one ASV contributing greater than half of the relative abundance).

Dirichlet-Multinomial Models of NoBPD and BPD infants:
Laplace analyses performed independently within the BPD or NoBPD cohorts identified 2 clusters as the best fit for each of these mycobiome subsets (supplemental figures S9d and g). In the NoBPD DMM model, membership in Cluster 1 was driven by *Saccharomyces*, *Aureobasidium*, and to a lesser extent a *Candida* ASV (supplemental figure S9h). Membership in Cluster 2 was driven by three different *Candida* ASVs and a *Saccharomyces* ASV. CCA suggests that membership in Cluster 1 associated with the the opposite clinical variables as NoBPD Cluster 1 (BW, GA and AMAB), with the exception of fungal abundance (supplemental figure S9i). In the BPD DMM model, membership in Cluster 1 was driven by *Saccharomyces* and *Candida* ASVs (supplemental figure S9e). Membership in Cluster 2 was primarily driven by an *Aureobasidium* ASV. On CCA, Cluster 1 was associated closely with BW and to a lesser extent with GA and death (supplemental figure S9f).

Bacterial DMM models:

DMM modeling using the bacterial microbiome data is shown in supplemental figures S10 and S11. Of note, Laplace clustering for the whole microbiome indicated optimal clustering with 4 clusters (supplemental figure S11a), while clustering for the NoBPD and BPD infants was optimal with 2 clusters, each (supplemental figures S11d and g). We then performed variable importance analysis and identified bacterial ASVs with significant contributions to component formation (supplemental figure S11). Clustering in the whole microbiome model is driven by *Enterococcus*, *Enterobacter*, *Cellulosimicrobium*, *Escherichia-Shigella* and multiple *Klebsiella* ASVs. Clustering in NoBPD infants was driven by *Enterococcus, Staphylococcus* and multiple *Klebsiella* ASVs, while Enterococcus and Enterobacter and *Klebsiella* ASVs drove the BPD infant clusters. CCA showed Cluster 2 of the overal bacterial model was associated with BPD, critical illness, AMAB and positive CRP (supplemental figure S9c). Together, the DMM clustering between the fungal and multikingdom microbiome models is not indicative of any significant overlap.

Figure S1. Source contamination modeling. a) Fungal taxa filtering loss plots. b) Bacterial taxa filtering loss plots. Please see tables of filtered taxa at github.com/WillisLungLab/MiBPD/SourceContamination. c) Average abundance of filtered fungal taxa. d) Average abundance of filtered bacterial taxa.

Figure S2. The BPD-associated mycobiome is unique. (a, b) Relative abundance of key fungi by DESeq2. (c,d) Relative abundance of key bacteria by DESeq2. (d) Number of edges in each SPIEC-EASI network. (e) Number of nodes in each SPIEC-EASI network. (e) Complete SPIEC-EASI BPD network with all genera labeled. (F) Complete NoBPD network with all genera labeled.

Figure S3. The overall composition of the multikingdom microbiome. (a) Alpha diversity. (c) Beta diversity (PCoA of Bray-Curtis dissimilarity, p = 0.0743, PERMANOVA, p = 0.3749, PERMDISP). Ellipses indicate the 95% confidence interval.

Figure S4. BPD status is predictable using machine-learning models of the fungal microbiota several weeks prior to the adjudication of the clinical diagnosis at 36 weeks corrected gestational age. (a-b) Exploratory random forest machine learning model using genera level mycobiome and clinical data (Should be considered exploratory due to high risk of overfitting). (c-d) Exploratory random forest machine learning model using genera-level bacterial microbiota and clinical data. (E) Directional variable importance analysis for the multikingdom light gradient boosted machine learning model.

Figure S5. Mycobiome features differences by sex assigned at birth. (a) Fungal alpha diversity. (b) Bacterial alpha diversity. Shannon diversity was decreased in infants assigned female at birth (AFAB) as compared to infants assigned male at birth (AMAB, p = 0.0427, Mann-Whitney). Simpson diversity was increased in infants AFAB as compared to those AMAB (p = 0.0239, Mann-Whitney). (c) Principal coordinates analysis of Bray-Curtis dissimilarity of fungal beta diversity (p = 0.2279, PERMANOVA; p = 0.9464, PERMDISP). (d) Principal coordinates analysis of Bray-Curtis dissimilarity of bacterial beta diversity (p = 0.7846, PERMANOVA; p = 0.3957, PERMDISP).

Figure S6. Microbiota alterations by disease status and sex assigned at birth. (a-b) DESeq2 selected features of the mycobiota. (c) SPIEC-EASI network edges. (d) SPIEC-EASI network nodes. (e) SPIEC-EASI networks for NoBPD infants assigned male at birth (AMAB) or assigned female at birth (AFAB). (f) SPIEC-EASI networks for BPD infants.

Figure S7. Oxygen concentration influences the composition of the intestinal microbiome. (A) PCoA of Bray-Curtis dissimilarity showing that the composition of the intestinal mycobiome is significantly associated with total weeks of exposure to oxygen (p = 0.1443, PERMANOVA). (B) PCoA of Bray-Curtis dissimilarity showing that the composition of the intestinal microbiome is not associated with total weeks of exposure to oxygen (p = 0.3902, PERMANOVA).

Figure S8. Unsupervised clustering analysis of heterogeneity in the mycobiome. (a) Dirichlet-Multinomial Mixture (DMM) model of the mycobiome. (b) Fungal community diversity analyses indicate higher microbial richness in Cluster 3. (c) Relative abundance of fungi in each DMM cluster. (d-f) A two-cluster DMM model in NoBPD infants, with the highest richness in Cluster 2. (g-i) A two-cluster DMM model in BPD infants with the highest microbial richness in Cluster 2. Clust1-5, Cluster 1-5. Ellipses indicate the 95% confidence interval.

Figure S9. Dirichlet-Multinomial Mixture (DMM) modeling of the mycobiome. (a) Laplace analysis of the mycobiome indicates optimal model fit points with 5 clusters. (b) Variable importance analysis of the fungal DMM model. (c) Canonical Correspondence Analysis (CCA) for the DMM model. (d) Laplace analysis of mycobiome samples from NoBPD infants shows an optimal fit point at 2 clusters. (e) Variable importance analysis of the NoBPD DMM model. (f) CCA for the NoBPD DMM model. (g) Laplace analysis of mycobiome samples from BPD infants shows an optimal fit point at 2 clusters. (h) Variable importance analysis of the BPD DMM model. (i) CCA for the BPD DMM model.

Figure S10. Dirichlet-Multinomial Mixture (DMM) modeling of the bacterial microbiome. (a) Principal Coordinates Analysis (PCoA) of the bacterial microbiome DMM model. (b) Alpha diversity of the bacterial microbiome DMM model. (c) Relative abundance of the bacterial microbiome in the DMM components. (d) PCoA of the DMM model of the bacterial microbiome of infants with NoBPD. (e) Alpha diversity of the multikingdom microbiome. (f) Relative abundance of the bacterial microbiome in the NoBPD DMM model. (g) PCoA of the DMM model of the bacterial microbiome of infants with BPD. (h) Alpha diversity of the bacterial microbiome. (i) Relative abundance of the multikingdom microbiome in the BPD DMM model. Ellipses indicated the 95% confidence interval.

Figure S11. DMM modeling of the bacterial microbiome. (a) Laplace analysis of the mycobiome indicates an optimal model fit point with four components. (b) Variable importance analysis of the multikingdom microbiome DMM model. (c) Canonical Correspondence Analysis (CCA) for the multikingdom microbiome DMM model. (d) Laplace analysis of multikingdom microbiome samples from NoBPD infants showing an optimal fit point at three components. (e) Variable importance analysis of the NoBPD DMM model. (f) CCA for the NoBPD DMM model. (g) Laplace analysis of multikingdom microbiome samples from BPD infants showing an optimal fit point at two components. (h) Variable importance analysis of the BPD DMM model. (i) CCA for the BPD DMM model.

Figure S12. Lung antimicrobial peptide expression. Heatmap of antimicrobial peptides.

Figure S13. Ingenuity pathway analysis. (A) Pathways in BPD-FMT mice. (B) Pathways in NoBPD-FMT mice. (C) Pathways in specific pathogen-free (SPF) mice.

Tables:

Table S1. Cohort characteristics and demographics

	NoBPD	BPD	n	*p*
Median (IQR) or n (%)	64	38		
Gestational age (weeks)	29.0 (27.6 - 30.8)	25.7 (25 - 27.8)	102	< 0.001
Birthweight (g)	1145 (840 - 1330)	775 (670 - 860)	102	< 0.001
Female sex assigned at birth	37/64 (57.8%)	14/38 (36.8%)	102	0.041
Antenatal Steroids (No)	8/47 (17%)	4/30 (13.3%)	77	0.33
Surfactant (None)	27/62 (43.5%)	1/38 (2.6%)	100	<0.001
Apgar score (1 min)	6 (3 - 7)	4 (2 - 5)	99	< 0.001
Apgar score (5 min)	7 (6 - 8)	6 (5 - 7)	99	< 0.001
Small for gestational age*	6/64 (9.4%)	8/38 (21.1%)	102	0.098
Ceasarean section (1)	28/47 (59.6%)	20/30 (66.7%)	77	0.531
Prolonged rupture of membranes** (1)	7/47 (15%)	5/30 (16.7%)	77	0.834
Critical Risk Index for Babies II (CRIB II) score	7 (4 - 9)	12 (9 - 14)	95	< 0.001
Prenatal antibiotic exposure	22/47 (46.8%)	15/30 (50%)	77	0.785
Duration of prenatal antibiotic exposure (d)	1 (0 - 1)	0 (0 - 1)	60	0.542
Postnatal antibiotic exposure	55/64 (85.9%)	38/38 (100%)	102	0.015
Duration of postnatal antibiotic exposure (d)	2 (1 - 2)	2 (1 - 4)	96	0.016
Endotracheal intubation	41/62 (66.1%)	37/37 (100%)	99	< 0.001
Ventilation duration (d)	1 (0 - 4)	34 (22 - 50)	94	< 0.001
Non-invasive ventilation duration (d)	5 (1 - 17)	14 (1 - 38)	94	0.053
Oxygen exposure duration (d)	13 (4 - 41)	92 (30 - 119)	94	< 0.001

Death	1/63 (1.6%)	6/38 (15.8%)	101	0.006

Data are presented as median (interquartile range) or n (%) with significance testing by Mann-Whitney U or Pearson chi-squared test, as appropriate.

BPD, Bronchopulmonary dysplasia; NoBPD, Post-prematurity respiratory disease. *< 3rd percentile, ‡ > 18 h, †NICHD Neonatal Outcomes Estimator

Table S2. Characteristics and demographics of infants without a stool for analysis

	Not Sequenced n = 42	Sequenced n = 102	Total N	P
Median (IQR) or n (%)				
Gestational age (weeks)	28.0 (26.1 - 29.8)	28.0 (25.8 - 30)	144	0.778
Birthweight (g)	950 (740 - 1160)	905 (760 - 1290)	144	0.733
Female sex assigned at birth	20/42 (47.6%)	51/51 (50%)	144	0.795
Antenatal Steroids (No)	10/35 (28.6%)	12/77 (15.6%)	112	0.421
Surfactant (None)	12/39 (30.8%)	28/100 (28.0)%	139	0.078
Apgar score (1 min)	4 (1 - 6)	5 (3 - 7)	133	0.26
Apgar score (5 min)	7 (5 - 8)	7 (5 - 8)	134	0.491
Small for gestational age*	4/42 (9.5%)	14/102 (13.7%)	144	0.488
Ceasarean section (1)	25/35 (71.4%)	48/77 (62.3%)	112	0.349
Prolonged rupture of membranes** (1)	7/35 (20.0%)	12/77 (15.6%)	112	0.564
Critical Risk Index for Babies II (CRIB II) score	9 (7 - 12)	9 (6 - 12)	134	0.499
Prenatal antibiotic exposure	22 (46.8%)	15 (50%)	112	0.323
Postnatal antibiotic exposure	37/42 (88.1%)	93/102 (91.2%)	144	0.571
Duration of postnatal antibiotic exposure (d)	2 (1 - 2)	2 (1 - 2)	133	0.635
Endotracheal intubation	30/41 (73.2%)	78/99 (78.8%)	140	0.471
Ventilation duration (d)	4 (0 - 16)	3 (0 - 26)	135	0.635
Non-invasive ventilation duration (d)	4 (1 - 15)	7 (1 - 19)	135	0.201

Oxygen exposure duration (d)	25 (8 - 68)	31 (8 - 76)	135	0.464		
Death	4/41 (9.8%)	11/142 (7.7%)	142	0.568		
BPD rates	19/41 (46.3%)	38/102 (37.3%)	143	0.316		

Table S3. PERMANOVA analysis of potential fungal covariates.

ITS Covariates	Sum of Squares	R^2	F	p	q (FDR)
Oxygen (days)	0.859912	0.040065	2.420743	0.010199	0.078192
Death	0.251176	0.01127	0.683911	0.785721	0.90358
Sex	0.454867	0.02041	1.250084	0.227877	0.403167
Gestational Age	0.502412	0.022543	1.383761	0.161084	0.308744
Birthweight	0.668982	0.030017	1.856733	0.045995	0.176316
CRIB-II	0.675101	0.030291	1.874244	0.044296	0.176316
Intubation	0.626614	0.028479	1.729528	0.062794	0.180762
Vent (days)	0.928147	0.043244	2.621516	0.005599	0.074743
Maternal UTI	0.291891	0.019745	0.90643	0.513049	0.737507
Preeclampsia	0.848091	0.05737	2.738757	0.006499	0.074743
Cesarean Section	0.568242	0.038439	1.798908	0.065493	0.180762
Multiples	0.128391	0.008685	0.394254	0.968403	0.968403
IUGR	0.361984	0.024487	1.129558	0.318868	0.523855
Feeding	1.249595	0.056793	0.842982	0.785421	0.90358
Prenatal Abx	0.220037	0.016129	0.704909	0.70443	0.90358
Postnatal Abx	0.60025	0.028093	1.676481	0.071393	0.180762
NEC	0.26655	0.012115	0.723522	0.765623	0.90358
Culture+ Sepsis	0.365213	0.016599	0.995854	0.410059	0.628757
Culture- Sepsis	0.507824	0.02308	1.393907	0.151385	0.308744

CRP	0.221336	0.009931	0.601845	0.857114	0.938744

Table S4. PERMANOVA analysis of potential bacterial covariates.

Bacterial Covariates	Df	Sum of Sqs	R^2	F	p	q (FDR)
Death	1	0.174478	0.005424	0.496284	0.986401	0.986401
Sex	1	0.259828	0.008077	0.74103	0.784622	0.859347
Gestational age	1	0.583988	0.018155	1.682631	0.037496	0.172483
Birthweight	1	0.738424	0.022956	2.138061	0.005999	0.10349
CRIB-II	1	0.630824	0.019611	1.820278	0.022698	0.130512
Feeding	4	1.383682	0.044219	0.994685	0.480952	0.655051
Oxygen (days)	1	0.526242	0.017615	1.524152	0.072893	0.20468
Vent (days	1	0.368035	0.01232	1.060221	0.373363	0.572489
Multiples	1	0.31171	0.013528	0.946218	0.484952	0.655051
IUGR	1	0.362514	0.015733	1.102904	0.322868	0.530426
Maternal UTI	1	0.297311	0.012903	0.901938	0.554045	0.663484
Preeclampsia	1	0.439966	0.019094	1.343129	0.161984	0.312769
Cesarean section	1	0.21574	0.009363	0.652141	0.838816	0.876944
Prenatal Abx	1	0.557406	0.026794	1.734477	0.008999	0.10349
Postnatal Abx	1	0.451244	0.014831	1.29471	0.163184	0.312769
NEC	1	0.309181	0.009881	0.888147	0.576942	0.663484
Intubation	1	0.537091	0.017164	1.55427	0.069293	0.20468
Culture+ sepsis	1	0.474332	0.015158	1.369859	0.123588	0.284252

Culture- sepsis	1	0.668253	0.021356	1.942117	0.015398	0.118055
CRP	1	0.329732	0.01037	0.943039	0.512649	0.655051

Table S5. Acute lung injury-associated genes differentially expressed in the lungs of BPD-FMT of NoBPD-FMT mice after hyperoxia-exposure.

Name	Max group means	Fold change	FDR p-value
Kit	34.89944	-4.31792	0.00176
Xdh	32.6964	-2.29232	0.001777
Selenbp1	691.6014	-2.159	0.002634
Serpine1	93.04131	2.07996	0.003799
Entpd1	30.32749	-1.69775	0.004522
Spp1	94.16831	3.160768	0.006071
Scgb1a1	72830.04	-2.6589	0.006085
Aldh1a1	847.4835	-2.52678	0.007888
Cyp2e1	10.74948	-7.94342	0.008407
Nos3	26.02174	-1.88547	0.009653
Pon1	17.50987	-2.57741	0.01097
Glul	255.4888	-2.21472	0.010973
Cdkn1c	111.4225	-1.88452	0.012053
Foxo1	22.12	-1.86653	0.012674
Fmo1	150.8291	-3.30259	0.012674
Igfbp5	232.0016	3.270017	0.014592
Calcrl	180.3053	-2.25981	0.021894
Pdgfra	21.07215	-2.31602	0.024421
Bmp2	7.261727	-1.81051	0.026813
Gsta3	112.2525	-1.91802	0.027736
Cd36	254.9841	-2.20231	0.027935

Gstm1	392.1433	-1.99292	0.029895
Cat	138.3049	-1.66712	0.030146
C3	259.0989	3.302059	0.032657
Abcc3	14.3485	-1.58457	0.044479
Ldhb	279.8842	-1.76503	0.046936
Bmp6	53.78907	-2.20148	0.051574
Por	207.6258	-1.59084	0.052883
Vegfc	20.26223	-1.63421	0.0592
Ramp2	675.0454	-2.1002	0.061152
Igf2	22.03991	2.062993	0.064629
Angptl4	105.475	-1.702	0.070517
Cd8a	4.319088	-3.01869	0.075015
F2r	122.1518	-1.53954	0.075671
Rgs4	17.95339	-1.70594	0.078622
Aldh2	324.0106	-1.70878	0.079467
Nr4a1	52.73562	2.337618	0.081358
Mapt	12.07152	-1.87042	0.081358
Flt1	19.94866	-1.70195	0.082077
Gsn	683.3746	-1.84827	0.082089
Tnfsf10	30.61867	-1.67666	0.085397
Pdgfrb	70.56528	-1.81923	0.088166
Hspa5	461.7231	1.675502	0.089573
Edn1	44.14402	-1.496	0.092682
Pltp	393.5593	-1.82991	0.098328
Hamp	9.390036	-4.40651	0.100104

Table S6. Lectins and other fungal-associated genes.

Name	Normoxia max group means	Fold change	FDR p-value	Hyperoxia max group means	Fold change	FDR p-value
Reg3g	125.7378	-10.4239	0.003688	162.3476	1.02955	0.992017
Clec5a	1.08385	1.087852	0.998991	2.712433	1.686155	0.418715
Clec4d	3.715903	1.193202	0.998991	8.32751	1.733554	0.313419
Clec10a	6.247333	-2.29367	0.528492	6.11558	-1.05898	0.96846
Colec11	3.914303	-1.52484	0.998991	4.594983	2.712321	0.115261
Cd302	49.55867	-1.06473	0.998991	81.59808	1.272356	0.526733
Mrc1	17.6641	-1.42096	0.998991	21.61832	1.057407	0.943666
Olr1	3.512283	-1.07582	0.998991	5.277159	1.164597	0.831115
Clec7a	31.76774	-1.17945	0.998991	41.95802	1.386064	0.46829
Clec12a	6.16115	-1.15362	0.998991	7.903554	1.191562	0.811886
Clec11a	8.423013	-1.33604	0.998991	8.940581	1.384451	0.59313
Clec3b	365.5351	-1.45895	0.906358	346.9807	1.054824	0.942974
Sftpd	802.4012	-1.40873	0.998991	896.616	-1.17443	0.768305
Clec2l	1.301569	-1.14745		1.483454	1.178183	0.921223
Pla2r1	4.668342	1.038428	0.998991	5.543161	1.070186	0.925283
Clec1a	35.80718	-1.11514	0.998991	48.076	-1.24911	0.638181
Clec9a	15.46983	-1.45215	0.998991	15.75296	-1.29182	0.63289
Layn	8.169843	-1.13391	0.998991	9.311215	-1.21783	0.653337
Mrc2	96.92931	-1.12035	0.998991	88.82867	1.156192	0.82189
Klrd1	2.481198	-1.00763		2.508489	1.181422	0.907133
Vcan	7.76357	1.374094	0.998991	7.116964	1.141553	0.898861
Dgcr2	53.08562	1.12667	0.998991	48.12952	-1.03824	0.952087
Colec12	101.9319	-1.03197	0.998991	90.5154	1.105169	0.864535
Atrn	11.93377	1.021454	0.998991	11.03505	-1.10897	0.81083

Gene						
Pkd1	25.75555	1.208233	0.998991	22.74798	-1.08504	0.894302
Frem1	21.77959	1.210365	0.998991	16.5999	1.258854	0.692306
Cd72	5.412205	1.243655	0.998991	7.491691	-1.71869	0.436089
Klrg1	1.821741	-2.17122		0.771923	-1.20194	0.92452
Sftpa1	973.3715	-1.26977	0.998991	995.9875	-1.57053	0.330538
Bcan	1.006777	-1.13803	0.998991	0.866189	-1.20371	0.902223
Cd93	106.9558	1.084508	0.998991	125.5295	-1.65012	0.149331
Atrnl1	16.04558	1.051649	0.998991	11.66754	-1.02127	0.973212
Cd69	1.811218	1.340058		1.5302	-1.18015	0.923925
Clec2d	219.5001	-1.18767	0.998991	152.6552	-1.06741	0.952087
Clec14a	114.9554	-1.33834	0.998991	132.072	-1.99149	0.036064
Clec12b	4.053577	1.105698	0.998991	2.915567	-1.11494	0.934748
Clec1b	5.444281	1.058832	0.998991	4.29238	-1.21047	0.85957
Thbd	261.6676	-1.12082	0.998991	259.302	-1.67356	0.114563
Prg2	8.766499	-2.14827	0.998991	2.055661	1.309011	0.910762
Sell	7.236587	1.584014	0.998991	5.452646	-1.77671	0.261235
Cd248	106.8494	1.15852	0.998991	42.13223	-1.20353	0.759667
Mbl2	1.115486	-1.74598		0.077049	1.439069	0.951451
Slpi	42.21049	-1.56242	0.998991	109.266	3.009375	3.74E-05
Hist1h2bc	125.2418	-1.0633	0.998991	195.9711	1.239957	0.50988
Clec7a	31.76774	-1.17945	0.998991	41.95802	1.386064	0.46829
Rarres2	387.2024	-1.2211	0.998991	472.3454	1.744679	0.032897
Senp8	1.319852	1.09805	0.998991	1.783109	1.418531	0.663881
Tlr4	3.687062	-1.0488	0.998991	5.190117	-1.04613	0.949032
Tlr2	6.261399	-1.09921	0.998991	7.540487	1.112188	0.889589
Hscb	26.01099	-1.23587	0.998991	25.40008	1.162098	0.817415

Name	Normoxia group means	Fold change	FDR p-value	Hyperoxia group means	Fold change	FDR p-value
Malt1	4.614531	1.090377	0.998991	4.951084	1.039782	0.964061
Hif1a	36.45999	1.205099	0.998991	39.2115	1.024301	0.972832
Camp	12.08179	-1.3274	0.998991	9.823168	1.48817	0.715914
Gps1	85.19948	1.189032	0.998991	85.20754	1.013453	0.983507
Hist2h2be	7.226456	1.001625	0.998991	7.375492	-1.0413	0.969961
Rel	1.266513	1.633626		1.45833	-1.17561	0.912653
Colec12	101.9319	-1.03197	0.998991	90.5154	1.105169	0.864535
Hist1h2bf	1.079463	-5.85598		0.129765	5.356575	
Hist1h2bg	3.325025	3.199163		2.524179	1.206217	0.931258
Prg2	8.766499	-2.14827	0.998991	2.055661	1.309011	0.910762

Table S7. Antimicrobial peptides differentially expressed after FMT.

Name	Normoxia group means	Fold change	FDR p-value	Hyperoxia group means	Fold change	FDR p-value
Slpi	42.21049	-1.56242	0.998991	109.266	3.009375	3.74E-05
C3	104.3676	-1.83015	0.998991	259.0989	3.302059	0.032657
Hp	427.7298	-1.18591	0.998991	1586.375	-2.09509	0.032792
Rarres2	387.2024	-1.2211	0.998991	472.3454	1.744679	0.032897
Pgc	12.03519	-1.12349	0.998991	10.94695	-2.22228	0.051338
Hamp	1.543867	-2.63589		9.390036	-4.40651	0.100104
Cxcr4	119.5874	-1.32268	0.998991	71.70755	-2.25683	0.121475
Nfkb1	51.99978	1.025438	0.998991	51.23847	-1.4143	0.167345
Cxcl12	46.71405	1.002714	0.998991	48.85411	-1.61724	0.202654
Wfdc2	1271.251	-1.44586	0.998991	1983.899	-1.49693	0.262351
Sgms1	20.98961	1.055461	0.998991	21.83559	-1.32873	0.3146
Sftpa1	973.3715	-1.26977	0.998991	995.9875	-1.57053	0.330538
Kng1	3.095511	-1.48806	0.998991	0.512236	9.051578	0.336817

Vdr	2.472601	-1.74366	0.845694	3.558433	-1.56409	0.337114
Cx3cl1	13.14899	-1.13212	0.998991	26.94542	-1.38715	0.392264
Sp1	20.62149	1.037774	0.998991	19.06398	-1.25174	0.411402
Cfh	29.88738	-1.43516	0.998991	47.05753	1.428474	0.418729
Ccl11	2.198763	-2.05959	0.998991	7.035486	-2.2147	0.421475
Crem	8.590571	1.518078	0.759497	7.695474	1.324896	0.452007
Tnf	1.305075	1.126893		2.72078	1.817019	0.456574
Cxcl14	54.08959	-1.66043	0.663675	43.41396	-1.37045	0.461501
Jun	159.1054	1.120591	0.998991	172.3009	-1.36043	0.47063
Tdo2	1.596041	-2.19046		2.392914	2.052647	0.503163
Hist1h2bc	125.2418	-1.0633	0.998991	195.9711	1.239957	0.50988
Msrb3	55.12583	-1.06169	0.998991	53.50053	-1.26596	0.528599
Ang	23.20214	-1.20193	0.998991	25.61818	1.294845	0.608422
Cxcl17	22.54323	-2.26996	0.721735	91.94383	-1.49096	0.619342
Il1b	3.338916	1.615907	0.998991	3.492186	1.486986	0.621237
Hes1	133.5566	1.052062	0.998991	131.4758	-1.2269	0.621604
Hist1h2bk	1.808745	1.413181		0.985548	2.144833	0.631939
Rela	79.71786	1.027902	0.998991	94.72069	-1.18425	0.655105
S100a9	166.6801	-1.01032	0.998991	161.909	1.246491	0.675218
Spink5	5.315213	-1.10439	0.998991	28.1719	-1.26824	0.701373
Becn1	108.8942	1.003	0.998991	119.2342	1.135035	0.705079
Cnot7	24.08492	1.186067	0.998991	23.42755	1.162634	0.706937
Cxcl10	1.935268	-2.34503	0.998991	6.204818	1.496931	0.711115
Camp	12.08179	-1.3274	0.998991	9.823168	1.48817	0.715914
Tlr9	1.165668	1.384931		1.335349	-1.48484	0.726409
Apoa1	61.84307	-1.94956	0.998991	5.337753	2.358199	0.727548
Ccl8	1.227995	-5.74286		7.090063	1.664119	0.731518

Cdk2ap1	252.7045	1.209843	0.998991	243.1286	1.123193	0.773319
Tfpi2	4.282193	-1.51916	0.998991	4.553553	1.289498	0.792932
Tslp	8.736732	-1.12402	0.998991	9.582609	-1.23706	0.794753
Vti1b	67.80921	-1.04054	0.998991	93.14723	1.110449	0.802953
Npc2	494.6179	-1.29795	0.998991	572.5572	-1.14261	0.814123
Pparg	3.069094	-1.0446	0.998991	4.417922	-1.1818	0.828452
Stat3	58.34777	-1.16825	0.998991	84.01726	-1.12177	0.833197
Cybb	15.21888	-1.15148	0.998991	14.79092	-1.12165	0.842363
Hmgn2	452.4994	-1.0379	0.998991	379.5816	1.109711	0.855161
Gapdh	290.0952	1.125191	0.998991	442.4618	-1.12938	0.856746
Mb21d1	2.130252	1.354239	0.998991	2.05978	1.186719	0.858003
Il15	5.373938	-1.18125	0.998991	5.346883	1.156065	0.868096
Ppbp	6.414731	1.094081	0.998991	6.011777	-1.17327	0.876869
Havcr2	2.131242	-1.29883	0.998991	2.935203	-1.15294	0.88705
Tlr2	6.261399	-1.09921	0.998991	7.540487	1.112188	0.889589
Lgals3	145.9186	-1.3409	0.998991	222.0462	-1.09566	0.894302
Napa	83.79143	1.075837	0.998991	85.8896	-1.06818	0.894541
Cxcl13	5.819985	-1.08454	0.998991	5.245195	-1.16793	0.895057
App	299.1855	1.05214	0.998991	296.2862	-1.08974	0.906914
Proc	1.064288	-1.26242		0.878119	-1.28091	0.907464
Rnase6	8.365637	-1.2137	0.998991	6.415788	-1.11427	0.908811
Tor2a	48.17959	1.051566	0.998991	49.46276	1.053002	0.920696
Vamp8	431.0809	-1.38513	0.998991	507.1844	1.06697	0.923896
Cst3	1943.699	-1.41758	0.998991	1767.558	-1.06819	0.92835
Hist1h2bg	3.325025	3.199163		2.524179	1.206217	0.931258
Fau	1928.524	-1.36534	0.998991	1567.658	-1.06487	0.931892
F2	3.282588	-3.11415	0.998991	0.39367	1.296238	0.936768

Name						
Ccl22	6.756708	-2.05366	0.484952	8.25575	-1.07868	0.943666
Bpifa1	3.793721	-1.10325	0.998991	56.08653	-1.18036	0.948831
Tlr4	3.687062	-1.0488	0.998991	5.190117	-1.04613	0.949032
Tnc	112.3146	1.212698	0.998991	71.42967	1.074485	0.949041
H2afj	189.4047	-1.23615	0.998991	294.892	1.051885	0.951327
Fam3a	29.6763	1.003286	0.998991	30.50283	-1.03195	0.957222
Pf4	60.49595	-1.40609	0.998991	90.3921	1.045774	0.957446
Hist1h2bj	1.651308	1.430272		0.894528	1.142567	0.965004
Slc11a1	5.474952	-1.10352	0.998991	7.670364	1.042333	0.96633
Egfr	3.780488	1.206189	0.998991	4.347085	-1.03936	0.96884
Hist2h2be	7.226456	1.001625	0.998991	7.375492	-1.0413	0.969961
Rnh1	146.5646	-1.02973	0.998991	188.5917	-1.02666	0.972261
Hif1a	36.45999	1.205099	0.998991	39.2115	1.024301	0.972832
Cxcl1	1.15729	-2.11011		2.982644	1.053812	0.979897
Creb1	13.89358	1.066996	0.998991	10.92437	1.017413	0.981625
Ltf	4.196515	-1.28453	0.998991	7.555468	-1.0327	0.983145
Tlr1	2.102284	1.215568	0.998991	1.932395	-1.0333	0.983507
Il33	28.69334	1.103731	0.998991	41.77179	-1.02124	0.98438
Ccl17	8.395478	-3.50481	0.099203	9.034659	1.021137	0.991657
Reg3g	125.7378	-10.4239	0.003688	162.3476	1.02955	0.992017
Prtn3	2.673962	-3.48481		2.427608	1.013256	0.99468
Nod2	2.896706	1.875412	0.899075	2.281065	1.008576	0.994959
Ccl25	2.515701	1.068979	0.998991	2.996855	-1.00803	0.995344
Hist1h2bf	1.079463	-5.85598		0.129765	5.356575	

Table S8. Genes uniquely regulated in the lungs of BPD-FMT mice as compared to conventional specific pathogen-free controls.

Name	Group Means	Fold change

Krt13	0.124047	-1.11895
Hist2h4	4.426621	3.576219
Krt6a	0.017139	1.424503
Gm38946	0.302418	-3.30277
Gm27252	0.619822	-1.96619
Cidea	0.62006	-3.92979
Stc2	1.263401	-1.73499
Adh7	2.142668	-2.23711
Fbxo16	0.901571	-1.48184
Krt5	0.063954	-13.2605
Fads6	0.446247	-1.26753
1700024G13Rik	6.054842	-3.19763
Dmkn	8.097874	-1.65057
A930003A15Rik	0.781178	-2.33375
Ces2e	3.042074	-1.79658
Cox6b2	52.67553	-1.25167
Krt15	2.898111	-1.76652
Marco	16.02968	-1.64974
Gas6	283.1856	-1.19699
Pmaip1	5.48126	-1.83258
Soat2	0.38445	-2.01658
Enho	44.96102	-1.1428
Ugt1a6b	6.395728	-1.83316
Gpr39	2.3569	-2.34735
Scgb3a1	227.9034	-6.19295
Spsb1	9.234821	-1.06946
Cd164l2	1.951027	-2.0344

Pde4b	45.94943	2.826633
Ecm1	51.20982	-1.31141
Gm15417	5.109488	-1.53456
Grip1	0.5721	-1.49763
Bst1	7.448012	-1.12787
A4galt	8.62264	-1.73582
Thrsp	1.580035	-1.71287
Espn	1.89898	-1.51822
Ccl6	251.0928	-1.18916
Bicd1	0.426641	-1.48441
Nrtn	32.85807	-1.34657
Aif1	12.09016	-1.5603
Col4a6	3.060502	-1.33718
Nupr1	314.5155	-1.7836
Adcy1	0.522839	1.029415
Il17re	10.34985	-1.17714
Ttc22	1.88672	-1.16168
Steap3	5.651359	-1.63151
Cox8b	12.99236	-2.41422
Igf2bp1	0.885084	-1.19676
1810041H14Rik	1.651538	-5.84915
Prkag3	4.239312	-1.29953
Cd200r4	1.171098	-1.23874
Ucp1	0.565499	-1.05181
C1qc	75.49035	-1.92014
Krt4	0.311152	-2.23965
Slc9a3r1	57.32879	-1.30708

Psca	0.316461	-6.0188
Gm36738	7.646624	-3.46044
Csf1	11.79775	-1.14297
2310040G24Rik	1.991402	-2.06863
Spib	12.10792	1.523361
Naprt	8.206917	-1.49933
Nos3	29.64505	1.315934
Cystm1	55.68114	-1.64711
Mreg	1.394614	-1.32031
2010107G23Rik	4.097872	-1.30864
Scrn1	3.409562	-1.42997
Guca1a	1.893324	-1.78875
Rhpn2	5.979036	-1.22996
4632428C04Rik	1.916809	1.029295
Sdf2l1	24.24535	-1.0663
Apol7a	0.192567	-1.12387
Sell	7.236587	1.584014
Ifit1	5.475209	-1.56213
Cd79b	68.33262	1.359754
Ms4a1	18.87741	1.88055
Lrp2	1.673435	-1.33702
S100a6	638.3225	-1.39352
C1ra	32.13626	-1.44138
Gm5859	1.098167	2.991254
Pou2af1	6.779359	1.487569
Neat1	58.25334	-1.29842
Fabp4	20.38431	-2.47988

Fcgr1	3.450381	-1.58257
Zbtb7c	1.478354	-1.87916
Tcf7	43.37252	1.329524
AW551984	0.475752	-1.53441
Itga6	51.15903	1.3071
Aebp1	22.07099	-1.25351
Slc16a1	12.39722	-1.40923
Cfh	29.88738	-1.43516
C1s1	41.33606	-1.41192
Zfp972	0.579094	-6.64571
Extl1	0.981818	-1.53824
Nnat	56.04459	-1.04295
Abca4	1.222806	-1.80214
Cpe	30.1561	-1.73075
Pag1	21.96902	1.223576
Rasgrp3	42.34212	1.256145
Smim22	36.90972	-2.68697
Foxp1	15.82618	-1.09337
Gm13139	4.747764	-1.48672
Cd19	19.84756	1.518108
Fmod	26.47954	-1.30475
Cpz	11.74204	-1.81953
Lrrn4cl	1.732488	-1.39299
Ces2g	4.46626	-1.81896
Msx1	6.8237	1.431806
Efemp1	32.36306	-1.30754
C330013E15Rik	1.577017	-3.58178

Pde3a	19.95015	1.149807
Naalad2	8.213686	1.130217
Myrf	13.57086	-1.05285
Cdon	2.122124	-1.08846
Trp53i11	30.37512	1.424501
Mybpc2	0.80593	-1.69681
Creb5	3.380476	1.692015
Fhod3	1.776046	1.448392
Tmem256	273.8812	-1.69405
Bbox1	1.299347	1.052629
Bmp2	14.38533	1.582495
Cacng7	10.48094	1.414488
Cdh2	6.236505	1.042197
Ntn1	25.73607	1.06862
Ephb1	2.049425	-1.65014
Lcat	7.156985	1.617303
Fbxl7	7.472116	1.257989
Fam65c	1.769985	-1.17398
Arhgap28	10.26519	1.522148
Sgip1	2.518465	1.2024
Pdgfrb	88.13611	-1.04472
Sipa1l2	38.36285	1.052311
B230208H11Rik	5.343494	-2.33188
Adgrg6	46.18953	1.110122
2200002D01Rik	75.65384	-1.84374
Atp5k	314.9772	-1.87132
Dchs1	11.72461	1.210916

Fer1l6	0.938931	-6.34029
Tbx5	35.66487	1.050854
Clip3	11.41685	1.193049
Smtn	71.28702	1.105576
Bach2	5.687495	1.117118
Arhgap42	27.95209	1.139126
Ildr2	1.29676	-1.09276
Sulf1	14.3649	-1.01288
Sdk2	1.8298	1.078807
Tmem200a	5.148806	1.006072
Ltbp2	186.5469	1.059819
Rnd1	5.310315	-1.78441
Tmem26	3.779252	1.112209
C3	104.3676	-1.83015
Troap	5.603836	1.327568
Hist1h3h	3.559671	3.66337
Angptl2	92.52887	1.071829
Podn	16.3895	-1.40194
Dact1	18.13796	-1.07005
Stac3	0.791794	-2.26831
Foxd2	1.157259	1.252542
Phactr3	1.563759	1.377351
Ntng2	14.47191	1.076578
Prr15	10.10169	-1.71893
Rcor2	4.859222	1.319022
Lsp1	119.7077	1.057556
Tpbgl	2.073025	-1.35603

Fam129a	33.72022	1.092119
Muc16	0.388227	-1.06405
Rnf165	1.438485	1.1768
Igsf10	9.006842	1.03677
Lrrc17	23.40947	-1.09634
Tff2	116.1078	-12.4211
Fam180a	5.055961	-1.66993
C4b	30.27749	-2.51276
C2	25.96561	-1.57529
Foxf2	109.0897	1.113748
Etv1	5.647585	1.211593
Rnf152	4.45432	1.051701
Ssc5d	17.31131	-1.0288
Acta1	14.11102	-12.3304
S100b	10.4393	1.001655
Astn2	9.474686	-1.19473
Fndc1	25.78409	1.239925
Galnt16	13.9438	1.043591
Cacnb2	8.749457	1.141458
Lgr6	7.373892	1.135033
Fbn2	5.825157	1.305934
Xlr4a	5.183054	-3.79566
Xist	36.02956	-3160.2
Smco3	7.248335	1.5229
Dgkb	1.365365	1.172055
Fbln7	1.820856	1.42218
Msln	150.7175	-1.50859

Gpm6a	14.31859	-1.55341
Nrg2	1.155046	-1.62519
Wt1	2.108712	-1.39932
Lgals2	6.100016	-1.24482
Pkhd1l1	1.085198	-1.77507
Sbsn	4.876373	-1.59509
Cldn15	11.90372	-1.53357
Rpp25	2.430225	-1.85105
Lrrn4	5.239606	-1.61104
Col11a1	0.331582	-1.80624
Sfrp2	27.68076	-1.89911
Clca1	227.7095	-27.8187
Upk3b	51.18176	-1.58497
Tnni2	3.097277	-3.96015
Mylpf	10.22943	-4.96784
Actn3	1.386666	-5.66022
2300002M23Rik	0.033995	-4.36944
Myoz1	0.795514	-13.2516
Cnfn	0.143162	-9.06496
Fgf8	0.279956	-2.77048
Tceal7	0.302268	-34.6209

Table S9. Genes uniquely regulated in the lungs of NoBPD-FMT mice as compared to conventional specific pathogen-free controls.

Name	Group means	Fold change
Zfp965	0.747088	27.2241
Olfm2	0.467526	2.779185

Them5	0.281256	1.36849
Gsta1	0.414415	1.659105
Agrp	0.427905	-1.4495
Gm35058	0.308317	1.680637
Erich3	0.177136	-1.29426
Rag1	0.299797	-1.55499
Hamp	1.543867	-2.63589
Gm3776	0.389215	-4.62476
Tbata	1.043634	-1.87272
AI463170	0.503266	-2.73976
Cd55b	0.36576	-3.59897
1700028P14Rik	2.06224	1.072707
Rsph4a	1.547444	1.082425
Ak9	0.438369	1.033955
Cfap161	1.055102	-1.14842
Gm28729	0.685688	-1.83326
Cdkl4	0.601068	-1.04215
Pih1h3b	0.394693	1.27077
Sptssb	0.615869	1.087073
Nek11	0.467898	-1.12244
Cfap46	0.404227	1.039963
Cfap73	0.718868	-1.40546
Aldh1a1	216.5887	-1.313
Foxj1	19.87813	-1.16116
Dnah12	0.489016	-1.14223
Fam216b	2.497301	1.010888
Armc4	0.538002	-1.29891

Cyp1b1	0.660795	1.181972
Ascl1	0.481965	-1.17225
Tcte1	1.602855	-1.04131
Ccdc13	0.460963	-1.0627
Drc7	2.268688	-1.56954
Muc20	0.8464	-1.13431
Kndc1	0.768254	-1.28838
Calca	0.426882	1.082337
Calcoco2	0.353991	-2.81471
Efcab6	0.325053	-1.06565
Snx31	0.793142	1.532751
Cfap58	0.762704	-1.33975
Hp	427.7298	-1.18591
Gm30571	1.346461	1.20637
Gdpd2	2.639634	1.022842
Spag17	0.579891	1.04001
Ccdc170	0.568654	-1.54091
Mdh1b	1.403813	-1.97822
Aldh3a1	8.810608	-1.80728
Ccdc60	0.975135	-1.2971
Itpka	3.669639	-1.21234
Zfp750	0.782552	-1.41017
1700001C02Rik	5.518053	-1.26097
Gabrp	11.58045	-1.30915
Tekt4	5.382539	-1.53163
Gm38655	1.536975	1.003124
Ccdc162	0.865232	-1.19717

Wdr63	1.963874	-1.40736
Foxn4	0.503122	1.173923
Fam131c	0.827337	1.335605
Pih1d2	3.506936	-1.14782
Dnah9	0.570002	-1.48074
Lhb	1.943497	1.300802
Fhad1	1.362772	-1.05895
6430531B16Rik	1.467733	-1.59546
Spef2	0.497839	-1.17717
Tnn	0.694614	1.030649
Meig1	5.307353	-1.43251
Ccdc40	2.559452	-1.27495
Fsip1	0.683191	-1.66926
Fgfbp1	8.425061	1.057735
Mfsd4b1	0.344117	-1.73546
Ccdc67	1.528175	-1.11535
Grhl1	1.382092	1.028995
Cd8a	1.495948	1.056372
Dydc2	0.671949	-2.23533
1700007G11Rik	2.646403	-1.55396
Kif6	0.381144	1.107188
Vnn3	5.242069	-1.19216
Ccdc39	1.630042	1.134776
Cfap77	1.392105	-1.0315
Ccdc96	0.871286	-1.23667
Stk33	1.2854	-1.1942
Atp2b2	0.474776	1.212464

BC051019	6.266007	-1.52234
Ccdc146	0.914636	-1.14127
Wdr78	1.457861	-1.05807
Lrrc74b	1.265719	-1.28206
Agbl2	1.137805	1.117841
Daw1	0.53615	1.524064
Efhb	0.51084	1.331564
Upk3a	4.323779	1.577925
Mak	1.404273	1.013156
Cckar	15.11284	1.024809
Pifo	6.738098	-1.38172
Bbof1	1.055621	-1.3895
Fank1	2.588348	-1.38615
1700088E04Rik	7.453328	-1.35488
Dlec1	0.764289	-1.38807
Cfap206	5.587028	-1.39798
Ubxn10	3.645057	-1.41526
Myb	3.611362	-1.03863
Cnga2	0.512242	1.293963
Ak7	2.201858	-1.79639
Enkur	6.157702	-1.47312
Ppil6	4.202134	-1.74787
Piwil4	1.171243	-1.0437
Ttc29	1.902104	-1.53659
Lrrc6	1.614015	-1.6742
Lrrc48	6.420338	-1.57716
Pcx	8.616838	-1.15521

Kif27	0.729145	-1.06882
Fbxo36	3.609376	-1.09305
1700016K19Rik	12.06757	-1.75303
Sult2b1	1.280956	1.168852
Map3k6	8.086206	1.352377
Cfap57	1.367506	-1.48746
Drc1	3.542837	-1.73753
Uckl1os	2.520573	-1.03977
D430036J16Rik	1.094228	-1.65224
Dcdc2a	0.513333	-1.39745
Zmynd10	3.18136	-1.39677
Aldh1a7	54.15298	-1.12571
Fsd2	0.697243	-1.46702
Cfap45	5.266718	-1.45386
Wdr66	2.550449	-1.28461
Lrrc46	3.595655	-1.78338
Nek5	1.123481	-1.59034
Ldhb	98.22047	-1.23276
Adgb	0.703214	-1.70152
Dsg2	0.969927	-1.12018
Samd5	0.742093	1.053904
Tekt1	7.357477	-1.45493
Gck	0.646637	-1.32291
Scara5	0.421486	-1.85349
Spag16	0.979761	-1.25648
Tex26	0.856559	-1.43939
Dnaaf1	2.092823	-1.33701

2610028H24Rik	10.15861	-1.46823
Zfp474	2.124752	-1.46467
Gsta4	70.10755	-1.26718
Ccdc151	2.196396	-1.78218
Trp73	1.005386	-1.2122
Gm1661	1.665125	-1.88985
Crocc2	1.309135	-1.02573
Fkbp5	6.992376	-1.16234
9530053A07Rik	0.420534	-1.32003
Hspa4l	3.597043	1.115255
Map3k7cl	3.6944	1.333931
Pon1	6.150858	-1.14073
Kcnmb2	0.618236	-1.41847
1700040L02Rik	1.104761	-1.42059
Ccdc108	2.011595	-1.17621
Slc35g1	1.834407	1.128848
Aim1l	0.728495	-1.32325
Cyp2f2	409.1582	-1.22294
Kif9	1.440004	-1.16828
Dnah11	0.832821	1.319302
Dnajb13	6.439244	-1.58067
Ccdc187	1.144283	-1.20572
Ace2	3.379031	-1.16499
Mycbpap	2.629436	-1.42255
Ttll6	0.722824	1.014257
Cep126	1.627121	1.08768
Ccdc78	5.18575	-1.61209

Fam183b	3.221229	-1.90569
Adora1	1.849945	1.084741
Aox3	7.421277	-1.18786
Lrrc26	19.06859	-1.37099
Celsr1	3.236459	1.163151
Kcnk12	1.927994	-1.94562
Slc39a4	16.13353	-1.27017
2410004P03Rik	9.349646	-1.51908
Ces1e	3.476821	-1.23535
Slc26a2	2.986595	1.544516
6820408C15Rik	2.943394	-2.2858
1700007K13Rik	14.76932	-1.80182
Chchd10	91.26994	-1.19021
Lyve1	172.7268	1.789494
Fam47e	2.470836	-1.64043
Dnaic2	2.863386	-1.1963
Gm973	0.619603	-1.82846
Rsph1	18.70821	-1.78589
Hspa1a	4.543204	1.045002
Sox2	5.933725	-1.8261
Efhc1	4.554399	-1.55961
Mall	5.428967	-1.02299
Scgb1a1	28881.56	-1.27235
Cfap100	1.91695	-1.24152
Gm867	6.033442	-1.81923
Fbxl2	0.906713	1.142327
Nphp4	0.730833	1.278639

Spag8	2.471477	-1.50517
Cldn10	11.83956	-1.1415
Eva1c	2.659558	-1.05769
1110017D15Rik	7.087448	-1.38299
Ubxn11	2.094496	-1.46259
Ccdc17	12.19577	1.031963
Entpd3	1.462285	1.033629
Ccdc30	1.351534	-1.09453
Atp7b	5.028835	1.079369
Lrrc10b	7.838019	-1.59563
Cfap43	2.467416	-1.22276
Lpar3	4.135293	-1.39213
P2ry2	12.37851	1.688393
Ankrd42	2.082838	-1.3643
Sec14l3	221.4122	-1.05763
Kcnk1	6.305701	1.295646
Disp2	6.908373	2.069988
Klf5	7.97893	1.046201
Cbr2	2747.85	-1.24996
Abcc3	6.745952	1.006725
Lrrc23	19.30216	-1.57015
Cfap126	13.55933	-1.50895
Pir	13.96118	-1.20878
Smad6	130.1713	1.894798
Ulk4	1.86953	-1.39591
Liph	6.935599	-1.01761
Kcnj15	9.0252	1.043461

Gfra1	2.070714	-1.17177
Mycl	5.430641	-1.24976
Slc16a7	2.006543	-1.30981
Traf3ip1	7.561994	-1.21545
Slc16a11	19.20798	-1.43762
5330417C22Rik	11.75453	-1.03641
Ildr1	4.180628	1.026268
Sh3bgrl2	8.884298	1.173207
Fam161a	2.812813	-1.09566
Tekt2	4.758059	-1.27468
Ehf	4.603814	-1.31594
Tmem116	6.736337	-1.16536
Scnn1a	64.88287	-1.17341
Gstm1	174.4655	-1.25008
Mgat3	4.033433	-1.00276
Dcxr	115.7401	-1.24589
Mapk15	8.34838	-1.18902
Atp1b1	130.2392	-1.16296
Fitm2	8.768173	1.287079
Ddi2	14.36509	1.424495
Ptgr1	16.87861	-1.1957
Mlph	4.555787	-1.16336
Ccdc181	11.6913	-1.54694
Ahcyl2	10.02024	1.042786
Erbb3	6.482798	1.377412
Cyfip2	3.764297	-1.0512
Tubb4b	337.6798	1.121257

Snhg8	52.73625	-1.89178
Etohd2	5.067122	1.007179
Gfra2	43.0271	-1.08521
Zfpm2	6.631144	1.034025
Gpr161	3.225496	1.097052
Wnt2	19.00554	1.060861
Gm4724	3.455679	-1.20361
Smarca1	5.978484	1.047574
Tmem86a	60.59845	-1.20303
Samd14	31.12983	1.061173
Rpl22l1	394.2313	-1.3966
Gjc2	11.21453	-1.05172
Gm5563	4.926049	-1.06783
Gpc2	10.17042	1.272041
C1qtnf3	2.926331	1.012192
Plp1	2.095942	-1.3622
Phtf1os	4.926127	-1.4521
Gpr173	2.615427	-1.01171
Rbp1	188.2611	-1.28178
LOC105247188	2.112084	-1.15055
Mdk	351.0079	-1.21657
Lncppara	13.85546	-1.10527
F10	7.218081	-1.52414
Slc5a3	2.98284	-1.08311
Cyp4f18	14.94618	-1.44632
H1fx	139.564	-1.80093
Duxbl2	1.558646	-1.01388

Hoxb3	8.690616	1.007857
LOC108169038	17.35673	-1.74224
Prr33	7.73516	1.753076
Gm14308	2.671789	-1.15287
Nrep	1464.195	-1.04472
Rab44	4.309702	1.038038
Proca1	4.997302	-1.26956
Cemip	3.683485	1.075804
Wdr86	3.993445	-1.13875
Duxbl1	1.450908	-1.16553
LOC102632302	3.371926	-1.08764
Prrx2	10.97686	-1.03934
Ankle1	3.297258	-1.02028
A730063M14Rik	17.44668	-2.35698
Mira	9.322291	-1.3571
Gdf10	18.15962	-1.31076
Gm5577	2.919654	-1.16202
Rpl37rt	4.08915	-1.47909
Slc4a1	13.15237	1.396093
Retnlg	64.23973	-1.47305
Amtn	6.047373	-1.75682
Gm5084	1.702609	-1.24492
Gm9918	1.33485	1.103891
Alas2	463.1282	1.151431
Gm11266	3.366341	-1.27451
Gm32031	7.156848	-3.25011
Snca	67.71871	-1.33209

Grin2c	2.392493	-1.33308
Cd5l	4.02251	-3.16244
Hoxaas2	6.297277	-1.54959
H19	84.03992	1.0415
Gm2102	1.408682	-1.71938
Gm32719	1.72775	-1.62104
3830403N18Rik	2.70625	-5.67054
Plac9a	538.6104	-6.63503
Zfp966	3.071118	-1.25468
Tspo2	2.40786	-1.22174
Lrat	2.433064	-2.25898
1300017J02Rik	1.164477	-1.79466
Gypa	12.51255	1.224549
Slurp1	80.33081	-1.28289
Asz1	1.406146	1.459921
2900009J06Rik	2.702584	-1.78277
Alox15	2.802077	-3.10958
Gm3650	4.458478	-2.17882
Tacr2	0.844891	-1.65745
Gm36416	1.053536	-4.13012
Prg2	8.766499	-2.14827
Prg4	2.68786	-4.37212
Apol11b	1.004739	1.02088
Afp	2.609795	-1.04037
Serpina11	1.003407	-4.17676
Apoa2	16.8805	-1.63416
Chil4	344.2854	-59.2423

F12	1.035451	-3.28371
Apom	2.738772	-1.11705
F2	3.282588	-3.11415
Fbp1	16.64172	-3.29611
Hgd	1.010647	-3.91013
Cyp2d26	1.34534	-1.1495
Pzp	2.173999	-2.90317
Sult2a2	2.164825	-11.2333
Gc	6.924776	-1.42864
Serpinc1	3.676805	-2.14539
Apoh	5.902545	-1.75957
Apoc4	5.40683	-2.1666
Mbl2	1.115486	-1.74598
Rnase2a	11.95903	-7.22571
Serpinf2	2.758101	-2.77372
Apof	1.397692	-1.66895
Ces1c	4.515406	-3.79905
Plg	2.775596	-2.19542
Cyp3a11	1.715403	-1.71206
Aldob	6.406132	-1.95662
Ambp	6.154407	-1.74727
Serpina1b	11.79677	-1.30102
Rdh7	1.444795	-2.92447
Ttr	26.3849	-1.35433
Alb	118.3806	-1.88962
Bhmt	5.487905	-1.76285
Mettl7b	1.217106	-1.27289

Sult2a1	1.571141	-6.16798
Serpina1d	5.009892	-1.90217
Serpina1c	8.847785	-1.23009
Serpina1a	10.94141	-1.382
Agxt	2.503928	-1.88474
Kng1	3.095511	-1.48806
Akr1c6	1.961807	-1.92619
Serpina1e	2.187371	1.044585
Fgb	3.71802	-1.96532
Hpd	3.237206	-2.43126

References:

1. Willis KA, Purvis JH, Myers ED, Aziz MM, Karabayir I, Gomes CK, Peters BM, Akbilgic O, Talati AJ, Pierre JF. Fungi form interkingdom microbial communities in the primordial human gut that develop with gestational age. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 2019; 33: 12825–12837.
2. Higgins RD, Jobe AH, Koso-Thomas M, Bancalari E, Viscardi RM, Hartert TV, Ryan RM, Kallapur SG, Steinhorn RH, Konduri GG, Davis SD, Thebaud B, Clyman RI, Collaco JM, Martin CR, Woods JC, Finer NN, Raju TNK. Bronchopulmonary Dysplasia: Executive Summary of a Workshop. *J Pediatrics* 2018; 197: 300–308.
3. Laughon MM, Langer JC, Bose CL, Smith PB, Ambalavanan N, Kennedy KA, Stoll BJ, Buchter S, Laptook AR, Ehrenkranz RA, Cotten CM, Wilson-Costello DE, Shankaran S, Meurs KPV, Davis AS, Gantz MG, Finer NN, Yoder BA, Faix RG, Carlo WA, Schibler KR, Newman NS, Rich W, Das A, Higgins RD, Walsh MC, Network EKSNI of CH and HDNR. Prediction of Bronchopulmonary Dysplasia by Postnatal Age in Extremely Premature Infants. *Am J Resp Crit Care* 2011; 183: 1715–1722.
4. Elm E von, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, Initiative S. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. *Plos Med* 2007; 4: e296.
5. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. 2010.
6. Staley C, Kaiser T, Beura LK, Hamilton MJ, Weingarden AR, Bobr A, Kang J, Masopust D, Sadowsky MJ, Khoruts A. Stable engraftment of human microbiota into mice with a single oral gavage following antibiotic conditioning. *Microbiome* 2017; 5: 87.
7. Chen X, Li P, Liu M, Zheng H, He Y, Chen M-X, Tang W, Yue X, Huang Y, Zhuang L, Wang Z, Zhong M, Ke G, Hu H, Feng Y, Chen Y, Yu Y, Zhou H, Huang L. *Gut* dysbiosis induces the development of pre-eclampsia through bacterial translocation. Gut 2020; : gutjnl-2019-319101.
8. Wrzosek L, Ciocan D, Borentain P, Spatz M, Puchois V, Hugot C, Ferrere G, Mayeur C, Perlemuter G, Cassard A-M. Transplantation of human microbiota into conventional mice durably reshapes the gut microbiota. *Scientific reports* 2018; 8: 6854.
9. Willis KA, Siefker DT, Aziz MM, White CT, Mussarat N, Gomes CK, Bajwa A, Pierre JF, Cormier SA, Talati AJ. Perinatal maternal antibiotic exposure augments lung injury in offspring

in experimental bronchopulmonary dysplasia. *American Journal of Physiology - Lung Cellular and Molecular Physiology* 2019; 3: 21.

10. Nardiello C, Mižíková I, Silva DM, Ruiz-Camp J, Mayer K, Vadász I, Herold S, Seeger W, Morty RE. Standardisation of oxygen exposure in the development of mouse models for bronchopulmonary dysplasia. *Disease models & mechanisms* 2017; 10: 185–196.

11. Ezz-Eldin ZM, Hamid TAA, Youssef MRL, Nabil HE-D. Clinical Risk Index for Babies (CRIB II) Scoring System in Prediction of Mortality in Premature Babies. *J Clin Diagnostic Res* 2015; 9: SC08-11.

12. Wang W, Yan T, Guo W, Niu J, Zhao Z, Sun K, Zhang H, Yu Y, Ren T. Constitutive GLI1 expression in chondrosarcoma is regulated by major vault protein via mTOR/S6K1 signaling cascade. *Cell Death Differ* 2021; 28: 2221–2237.

13. Nicola T, Ambalavanan N, Zhang W, James ML, Rehan V, Halloran B, Olave N, Bulger A, Oparil S, Chen Y-F. Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. American Journal of Physiology - Lung Cellular and Molecular Physiology 2011; 301: L125-34.

14. Nicola T, Hagood JS, James ML, MacEwen MW, Williams TA, Hewitt MM, Schwiebert L, Bulger A, Oparil S, Chen Y-F, Ambalavanan N. Loss of Thy-1 inhibits alveolar development in the newborn mouse lung. *Am J Physiol-lung C* 2009; 296: L738–L750.

15. Baker JM, Hinkle KJ, McDonald RA, Brown CA, Falkowski NR, Huffnagle GB, Dickson RP. Whole lung tissue is the preferred sampling method for amplicon-based characterization of murine lung microbiota. Microbiome 2021; 9: 99.

16. Pierre JF, Phillips GJ, Chandra LC, Rendina DN, Thomas-Gosain NF, Lubach GR, Lyte M, Coe CL, Gosain A. Lyticase Facilitates Mycobiome Resolution Without Disrupting Microbiome Fidelity in Primates. *J Surg Res* 2021; 267: 336–341.

17. Tiew PY, Dicker AJ, Keir HR, Poh ME, Pang SL, Aogáin MM, Chua BQY, Tan JL, Xu H, Koh MS, Tee A, Abisheganaden JA, Chew FT, Miller BE, Tal-Singer R, Chalmers JD, Chotirmall SH. A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD. *Eur Respir J* 2021; 57: 2002050.

18. Ali NABM, Aogáin MM, Morales RF, Tiew PY, Chotirmall SH. Optimisation and Benchmarking of Targeted Amplicon Sequencing for Mycobiome Analysis of Respiratory Specimens. *Int J Mol Sci* 2019; 20: 4991.

19. Jilling T, Ren C, Yee A, Aggarwal S, Halloran B, Ambalavanan N, Matalon S. Exposure of neonatal mice to bromine impairs their alveolar development and lung function. American Journal of Physiology - Lung Cellular and Molecular Physiology 2018; 314: L137–L143.

20. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ, Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, Brejnrod A, Brislawn CJ, Brown CT, Callahan BJ, Caraballo-Rodríguez AM, Chase J, Cope EK, Silva RD, Diener C, Dorrestein PC, Douglas GM, Durall DM, Duvallet C, Edwardson CF, Ernst M, Estaki M, Fouquier J, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat Biotechnol* 2019; 37: 852–857.

21. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. *Nature methods* 2016; 13: 581–583.

22. Smirnova E, Huzurbazar S, Jafari F. PERFect: PERmutation Filtering test for microbiome data. *Biostatistics* 2018; 20: 615–631.

23. Doupe P, Faghmous J, Basu S. Machine Learning for Health Services Researchers. *Value Health* 2019; 22: 808–815.

24. Karabayir I, Goldman SM, Pappu S, Akbilgic O. Gradient boosting for Parkinson's disease diagnosis from voice recordings. *Bmc Med Inform Decis* 2020; 20: 228.

25. Ansotegui C, Sellmann M, Shah T, Tierney K. Learning How to Optimize Black-Box Functions With Extreme Limits on the Number of Function Evaluations. *Arxiv* 2021; .

26. Holmes I, Harris K, Quince C. Dirichlet Multinomial Mixtures: Generative Models for Microbial Metagenomics. *Plos One* 2012; 7: e30126.